ASIA VITAL COMPONENTS CO. , LTD

AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

WITH REPORT OF INDEPENDENT ACCOUNTANTS

FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024

Address: No.248-27, Xinsheng Rd., Qianzhen Dist., Kaohsiung City 806, Taiwan (R.O.C.)
Telephone: 886-7-815-7612

The reader is advised that these consolidated financial statements have been prepared originally in Chinese. In the event of a conflict between these financial statements and the original Chinese version or difference in interpretation between the two versions, the Chinese financial statements shall prevail.

安永聯合會計師事務所

80052 高雄市中正三路2號17樓
17F, No.2, Zhongzheng 3rd Road
Kaohsiung City, Taiwan, R.O.C

Tel: 886 7 238 0011
Fax: 886 7 237 0198
www.ey.com/taiwan

REVIEW REPORT OF INDEPENDENT ACCOUNTANTS

English Translations of a Report Originally Issued in Chinese

To Asia Vital Components Co., Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of Asia Vital Components Co., Ltd. and subsidiaries (collectively, the "Company ") as of March 31, 2025 and 2024, the related consolidated statements of comprehensive income for the three-month periods ended March 31, 2025 and 2024 and consolidated statements of changes in equity and cash flows for the three-month periods ended March 31, 2025 and 2024, and notes to the consolidated financial statements, including the summary of significant account policies (together "the consolidated financial statements"). Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" as endorsed and became effective by Financial Supervisory Commission of the Republic of China, Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, ”Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As discussed in Note, certain non-significant subsidiaries included in the consolidated financial statements were unreviewed. These subsidiaries' total assets amounted to NT$24,601,426 thousand and NT$14,957,250 thousand, or 22% and 20% of the total consolidated assets as of March 31, 2025 and 2024, respectively. These subsidiaries' total liabilities amounted to NT$15,694,386 thousand and NT$8,425,098 thousand, or 20% and 17% of the total consolidated liabilities as of March 31, 2025 and 2024, respectively. The comprehensive income of these subsidiaries amounted to NT$381,993 thousand and NT$66,174 thousand, or 9% and 3% of the consolidated comprehensive income for the three-month periods ended March 31, 2025 and 2024 respectively. As discussed in Note 6(9) to consolidated financial statements mentioned, the investments accounted for under the equity method were NT$604,150 thousand and NT$395,087 thousand as of March 31, 2025 and 2024, respectively. The share of income of associates under the equity method amounted to (NT$44,292) thousand and NT$25,722 thousand for the three-month periods ended March 31, 2025 and 2024, respectively. The share of the other comprehensive income of associates under the equity method amounted to NT$2,626 thousand and (NT$3,854) thousand for the three-month periods ended March 31, 2025 and 2024, respectively. These amounts were based on the investees' unreviewed financial statements. The information on Note 13 to consolidated financial statements was not reviewed by the independent accountants.

Qualified Conclusion

Based on our reviews, except for the information of certain non-significant subsidiaries and investees mentioned in the Basis for Qualified Conclusion paragraph where were based on the unreviewed financial statements that might be adjusted if they were reviewed by the independent accountants, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of March 31, 2025 and 2024, their consolidated financial performance for the three-month periods ended March 31, 2025 and 2024, and cash flows for the three-month periods ended March 31, 2025and 2024, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" as endorsed and became effective by Financial Supervisory Commission of the Republic of China.

ERNST & YOUNG
Taiwan
Republic of China
May 13, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, results of operations and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions, The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

English translation of Consolidated Financial Statements Originally issued in Chinese

ASIA VITAL COMPONENTS CO., LTD

CONSOLIDATED BALANCE SHEETS

As of March 31, 2025, December 31, 2024 and March 31, 2024

(March 31, 2025 and 2024 are unaudited)

(Expressed in thousands of New Taiwan Dollars)

		March 31, 2025		December 31, 2024		March 31, 2024	
Assets	Notes	Amount	%	Amount	%	Amount	%
Current assets							
Cash and cash equivalents	6(1)	$34,491,933	31	$29,923,508	30	$28,837,601	38
Financial assets measured at amortized costs, current	6(2), 8	3,964,515	4	2,075,672	2	2,194,604	3
Notes receivable, net	4, 6(3)	1,460,383	1	1,305,637	1	837,648	1
Accounts receivable, net	4, 6(4)	3,448,221	3	6,461,331	6	4,622,199	6
Other receivables	6(4).(5)	690,368	1	533,799	1	648,232	1
Other receivables-related parties	6(5)	3,929	0	5,681	0	5,514	0
Inventories, net	6(6)	39,584,561	35	33,397,345	33	18,523,927	25
Prepayments	6(7)	899,747	1	751,509	1	618,127	1
Other current assets		1,673,165	1	1,637,875	2	804,806	1
Total current assets		86,216,822	77	76,092,357	76	57,092,658	76
Non-current assets							
Financial assets measured at fair value through other comprehensive income, noncurrent	4, 6(8)	435,739	0	493,663	1	161,236	0
Financial assets at amortized cost, noncurrent	6(2)	33,138	0	32,719	0	31,934	0
Investments accounted for under the equity method	6(9)	604,150	1	636,808	1	395,087	1
Property, plant and equipment	4, 6(10), 8	14,707,608	13	13,805,248	14	11,715,885	16
Right-of-use assets	4, 6(23), 8	3,111,062	3	3,019,998	3	1,735,395	2
Investment property	4, 6(11), 8	297,064	0	268,763	0	124,479	0
Intangible assets	6(12)	161,320	0	168,667	0	169,010	0
Deferred tax assets	4, 6(27)	1,316,206	1	1,296,010	1	1,255,399	2
Other non-current assets	6(13), 8	4,905,131	5	4,054,739	4	2,087,459	3
Net defined benefit assets, noncurrent	4, 6(19)	36,422	0	36,589	0	17,707	0
Total non-current assets		25,607,840	23	23,813,204	24	17,693,591	24
Total assets		$111,824,662	100	$99,905,561	100	$74,786,249	100

(The accompanying notes are an integral part of the consolidated financial statements.)

English translation of Consolidated Financial Statements Originally issued in Chinese

ASIA VITAL COMPONENTS CO., LTD

CONSOLIDATED BALANCE SHEETS

As of March 31, 2025, December 31, 2024 and March 31, 2024

(March 31, 2025 and 2024 are unaudited)

(Expressed in thousands of New Taiwan Dollars)

		March 31, 2025		December 31, 2024		March 31, 2024	
Liabilities and Equity	Notes	Amount	%	Amount	%	Amount	%
Current liabilities							
Short-term loans	6(14)	$10,225,347	9	$9,585,252	10	$5,894,360	8
Contract liabilities, current	6(22)	2,116	0	2,881	0	876	0
Notes payable		7,365,572	7	5,192,111	5	4,379,435	6
Accounts payable		25,297,537	23	23,691,532	24	14,829,270	20
Other payables	6(15)	12,958,952	12	7,924,925	8	9,403,832	12
Current tax liabilities	4, 6(27)	3,397,433	3	2,491,022	2	2,137,028	3
Lease liabilities, current	4, 6(23)	382,175	0	335,637	0	271,907	0
Other current liabilities		7,115,402	6	5,520,145	5	2,925,136	4
Current portion of long-term loans	6(16).(17)	3,650,774	3	3,544,621	4	886,573	1
Total current liabilities		70,395,308	63	58,288,126	58	40,728,417	54
Non-current liabilities							
Corporate bonds payable	6(16)	－	－	－	－	2,400,000	3
Long-term loans	6(17)	3,323,900	3	3,348,795	3	2,765,300	4
Deferred tax liabilities	4, 6(27)	2,031,441	2	2,135,455	2	2,088,631	3
Lease liabilities, noncurrent	4, 6(23)	2,013,985	2	1,960,515	2	869,182	1
Long-term deferred revenue	6(18)	667,850	0	661,136	1	671,657	1
Guarantee deposits		39,446	0	38,659	0	36,214	0
Total non-current liabilities		8,076,622	7	8,144,560	8	8,830,984	12
Total liabilities		78,471,930	70	66,432,686	66	49,559,401	66
Equity attributable to the parent company							
Capital	6(20)						
Common stock		3,876,951	4	3,875,535	4	3,833,101	5
Capital collected in advance		23,317	0	6,995	0	－	－
Additional paid-in capital	6(20)	2,549,863	2	3,546,404	4	3,377,804	5
Retained earnings	6(20)						
Legal reserve		2,298,983	2	2,298,983	2	1,768,785	2
Special reserve		1,451,514	1	1,451,514	2	1,119,685	2
Undistributed earnings		18,800,245	17	18,300,365	18	12,540,395	17
Total retained earnings		22,550,742	20	22,050,862	22	15,428,865	21
Other components of equity		(153,620)	(0)	(609,162)	(1)	(1,143,965)	(2)
Total equity attributable to the parent company		28,847,253	26	28,870,634	29	21,495,805	29
Non-controlling interests	6(20)	4,505,479	4	4,602,241	5	3,731,043	5
Total equity		33,352,732	30	33,472,875	34	25,226,848	34
Total liabilities and equity		$111,824,662	100	$99,905,561	100	$74,786,249	100

(The accompanying notes are an integral part of the consolidated financial statements.)

English translation of Consolidated Financial Statements originally issued in Chinese

ASIA VITAL COMPONENTS CO., LTD

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

As of March 31, 2025, March 31, 2024

(March 31, 2025 and 2024 are unaudited)

(Expressed in thousands of New Taiwan Dollars, except for earnings per share)

Items	Notes	For the three-month period ended March 31, 2025		For the three-month period ended March 31, 2024	
		Amount	%	Amount	%
Operating revenues	4, 6(22)	$23,332,951	100	$15,308,688	100
Operating costs	6(23).(24)	(17,304,991)	(74)	(11,936,305)	(78)
Gross profit		6,027,960	26	3,372,383	22
Operating expenses	6(23).(24)				
Sales and marketing expenses		(328,223)	(1)	(262,813)	(2)
General and administrative expenses		(252,029)	(1)	(211,025)	(1)
Research and development expenses		(1,102,021)	(5)	(976,699)	(6)
Expected credit impairment (losses) gains		15,183	0	13,052	0
Subtotal		(1,667,090)	(7)	(1,437,485)	(9)
Operating income		4,360,870	19	1,934,898	13
Non-operating income and expenses					
Interest income	6(25)	106,663	1	95,586	0
Other income	6(25)	319,433	1	278,175	2
Other gains and losses	6(25)	15,745	0	97,309	1
Finance costs	6(25)	(138,058)	(1)	(102,082)	(1)
Share of profit or loss of associates	4, 6(9)	(44,292)	0	25,722	0
Subtotal		259,491	1	394,710	2
Income from continuing operations before income tax		4,620,361	20	2,329,608	15
Income tax expense	6(27)	(1,110,270)	(5)	(579,430)	(4)
Net income		3,510,091	15	1,750,178	11
Other comprehensive income (loss)	6(26)				
Items that will not be reclassified subsequently to profit or loss:					
Remeasurements of defined benefit pension plans					
Unrealized gains (losses) from equity instruments investments measured at fair value through other comprehensive income		(58,428)	(0)	(4,631)	(0)
Income tax related to items that will not be reclassified					
Items that may be reclassified subsequently to profit or loss:					
Exchange differences on translation of foreign operations		617,685	2	498,398	4
Share of other comprehensive income (loss) of associates		2,626	0	(3,854)	(0)
Income tax related to items that may be reclassified subsequently		(43,551)	(0)	(141,454)	(1)
Total other comprehensive loss, net of tax		518,332	2	348,459	3
Total comprehensive income		$4,028,423	17	$2,098,637	14
Net income attributable to:					
Stockholders of the parent		$3,213,746	14	$1,564,017	10
Non-controlling interests		296,345	1	186,161	1
		$3,510,091	15	$1,750,178	11
Comprehensive income (loss) attributable to:					
Stockholders of the parent		$3,669,288	16	$1,871,566	12
Non-controlling interests		359,135	1	227,071	2
		$4,028,423	17	$2,098,637	14
Earnings per share (NTD)	4, 6(28)				
Earnings per share-basic		$8.28		$4.08	
Earnings per share-diluted		$8.06		$3.95	

(The accompanying notes are an integral part of the consolidated financial statements.)

English translation of Consolidated Financial Statements originally issued in Chinese

ASIA VITAL COMPONENTS CO. , LTD

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

For the three-month periods ended March 31, 2025 and 2024

(Expressed in thousands of New Taiwan Dollars)

	Equity Attributable to the Parent Company										
	Capital			Retained Earnings			Other Components of Equity				
Items	Common Stock	Advance receipts for share capital	Additional Paid-in Capital	Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translation of Foreign Operations	Unrealized Gains (Losses) From Equity Instruments Investments Measured At Fair Value Through Other Comprehensive Income	Total	Non-Controlling Interests	Total Equity
Balance as of January 1, 2024	$3,833,101	—	$3,866,691	$1,768,785	$1,119,685	$12,892,929	($1,126,528)	($324,986)	$22,029,677	$3,817,401	$25,847,078
Appropriation and distribution of 2023 retained earnings											
Cash dividends						(1,916,551)			(1,916,551)		(1,916,551)
Donation from shareholders			212						212		212
Capital surplus cash payment			(766,620)						(766,620)		(766,620)
Income for the three-month ended March 31, 2024						1,564,017			1,564,017	186,161	1,750,178
Other comprehensive income (loss) for the three-months ended March 31, 2024							312,180	(4,631)	307,549	40,910	348,459
Total comprehensive income (loss)	—	—	—	—	—	1,564,017	312,180	(4,631)	1,871,566	227,071	2,098,637
Cash capital increase									-		-
Share-based payment transaction			277,521						277,521		277,521
Decrease in non-controlling interests									—	(313,429)	(313,429)
Proceeds from disposal of financial assets at fair value through other comprehensive income									—		—
Balance as of March 31, 2024	$3,833,101	—	$3,377,804	$1,768,785	$1,119,685	$12,540,395	($814,348)	($329,617)	$21,495,805	$3,731,043	$25,226,848
Balance as of January 1, 2025	$3,875,535	$6,995	$3,546,404	$2,298,983	$1,451,514	$18,300,365	($539,526)	($69,636)	$28,870,634	$4,602,241	$33,472,875
Appropriation and distribution of 2023 retained earnings											
Cash dividends						(2,713,866)			(2,713,866)		(2,713,866)
Donation from shareholders			178						178		178
Cash dividends distributed from capital surplus			(1,163,086)						(1,163,086)		(1,163,086)
Income for the three-month ended March 31, 2025						3,213,746			3,213,746	296,345	3,510,091
Other comprehensive income (loss) for the three-months ended March 31, 2024							513,970	(58,428)	455,542	62,790	518,332
Total comprehensive income (loss)	—	—	—	—	—	3,213,746	513,970	(58,428)	3,669,288	359,135	4,028,423
Share-based payment transaction	1,416	16,322	166,367						184,105		184,105
Decrease in non-controlling interests									—	(455,897)	(455,897)
Balance as of March 31, 2025	$3,876,951	$23,317	$2,549,863	$2,298,983	$1,451,514	$18,800,245	($25,556)	($128,064)	$28,847,253	$4,505,479	$33,352,732

(The accompanying notes are an integral part of the consolidated financial statements.)

English translation of Consolidated Financial Statements originally issued in Chinese
ASIA VITAL COMPONENTS CO., LTD
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the three-month periods ended March 31, 2025 and 2024
(Expressed in thousands of New Taiwan Dollars)

Items	For the three-month periods ended March 31, 2025	For the three-month periods ended March 31, 2024
Cash flows from operating activities:		
Net income before tax	$4,620,361	$2,329,608
Adjustments to reconcile net income before tax to net cash provided by operating activities:		
Income and expanse adjustments :		
Depreciation	747,757	536,989
Amortization	13,087	20,195
Amortization of royalty	219	221
Amortization of patents	—	95
Expected credit (profit)	(15,183)	(13,052)
Interest expense	138,058	102,082
Interest income	(106,663)	(95,586)
Compensation costs of share-based payment transaction	160,788	277,521
Share of (profit) losses of associates	44,292	(25,722)
Loss on disposal of property, plant and equipment	31,910	15,687
Impairment loss on non-financial assets	12,821	—
Others	854,232	375,083
Changes in operating assets and liabilities:		
Notes receivable	(156,095)	(54,425)
Accounts receivable	2,942,431	1,077,063
Other receivables	(78,646)	61,180
Other receivables-related parties	1,752	2,441
Inventories	(7,113,540)	(1,711,110)
Prepayments	(148,238)	(57,029)
Other current assets	(35,290)	3,765
Other operation assets	(1,888,843)	(60,326)
Contract liabilities	(765)	360
Notes payable	2,173,461	717,789
Accounts payable	1,606,005	(282,130)
Other payables	698,750	278,286
Other current liabilities	1,595,435	518,707
Net defined benefit liabilities	167	8
Cash generated from operations	6,098,263	4,017,700
Interest received	114,119	103,508
Interest paid	(135,630)	(100,316)
Income tax paid	(371,620)	(194,024)
Net cash provided by operating activities	5,705,132	3,826,868
Cash flows from investing activities:		
Acquisition of property, plant and equipment	(1,359,426)	(622,056)
Proceeds from disposal of property, plant and equipment	97	640
(Increase) in refundable deposits	(5,978)	(4,741)
Acquisition of intangible assets	(2,960)	(10,357)
(Increase) Decrease in other noncurrent assets-others	(843,841)	(515,055)
(Increase) in other prepayments	(1,014)	(2,029)
Net cash used in investing activities	(2,213,122)	(1,153,598)
Cash flows from financing activities:		
Increase in short-term loans	5,286,173	2,248,332
(Decrease) in short-term loans	(4,809,972)	(3,204,520)
(Decrease) in short-term notes payable	—	(30,000)
Proceeds from long-term loans	660,000	160,000
Repayments of long-term loans	(582,516)	(281,673)
Increase in guarantee deposits	787	711
Repayment of lease liabilites	(105,264)	(67,649)
Issuance of common stock for cash	23,317	—
Net cash provided by financing activities	472,525	(1,174,799)
Effect of exchange rate changes on cash and cash equivalents	603,890	382,161
Net increase in cash and cash equivalents	4,568,425	1,880,632
Cash and cash equivalents at beginning of year	29,923,508	26,956,969
Cash and cash equivalents at end of year	$34,491,933	$28,837,601

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translation of Financial Statements Originally Issued in Chinese

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE -MONTH PERIODS ENDED MARCH 31, 2025 AND 2024

(Unless otherwise stated, all amounts expressed are in thousands of New Taiwan Dollars)

1. History and organization

ASIA VITAL COMPONENTS CO., LTD. (the Company) was incorporated on December 17, 1991. The Company's registered address is No.248-27, Xinsheng Rd., Qianzhen Dist., Kaohsiung City. The principal activities of the Company are to manufacture, process, assemble and to import and export electronic parts, electronic materials, communication electronic machinery products, automobile parts, lighting device, computer peripherals.

The Company's ordinary shares were publicly listed on the Taiwan Stock Exchange (TWSE) on 27 September, 2002.

2. Date and procedures of authorization of financial statements for issue

The consolidated financial statements of the Company and its subsidiaries ("the Group") for the three - month periods ended MARCH 31, 2025 and 2024 were authorized for issue by the Board of Directors on May 13, 2025.

3. NEWLY ISSUED OR REVISED STANDARDS AND INTERPRETATIONS

(1) Changes in accounting policies resulting from applying for the first time certain standards and amendments.

The Group adopted International Financial Reporting Standards, International Accounting Standards, and Interpretations issued, revised or amended which are recognized by Financial Supervisory Commission ("FSC") and become effective for annual periods beginning on or after January 1, 2025. The adoption of these new standards and amendments had no material impact on the Group.

(2) The Q&A related to the early application of certain amendments to IFRS 9 and IFRS 7 "Amendments to the Classification and Measurement of Financial Instruments" issued by the FSC, which has not yet been adopted by the Group as at the date when the Group's financial statements were authorized for issue.

In the Q&A, only Section 4.1 (Classification of Financial Assets) of the application guidance is allowed to early adopt from 1 January 2025. Additionally, entities must also comply with the requirements of paragraphs 20B, 20C and 20D of IFRS 7 and disclose the fact of early adoption of these amendments in the financial statements.

(3) Standards or interpretations issued, revised or amended, by International Accounting Standards Board ("IASB") which have not been endorsed by FSC, and not yet adopted by the Group as at the date when the Group's financial statements were authorized for issue, are listed below:

Items	New, Revised or Amended Standards and Interpretations	Effective Date issued by IASB
a	IFRS 10 "Consolidated Financial Statements" and IAS 28 "Investments in Associates and Joint Ventures" — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures	To be determined by IASB
b	IFRS 17 "Insurance Contracts"	1 January 2023
c	IFRS 18 "Presentation and Disclosure in Financial Statements"	1 January 2027
d	Disclosure Initiative – Subsidiaries without Public Accountability: Disclosures (IFRS 19)	1 January 2027
e	Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7	1 January 2026
f	Annual Improvements to IFRS Accounting Standards – Volume 11	1 January 2026
g	Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7	1 January 2026

A. IFRS 10 "Consolidated Financial Statements" and IAS 28 "Investments in Associates and Joint Ventures" — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures

The amendments address the inconsistency between the requirements in IFRS 10 *Consolidated Financial Statements and IAS 28 Investments in Associates and Joint Ventures*, in dealing with the loss of control of a subsidiary that is contributed to an associate or a joint venture. IAS 28 restricts gains and losses arising from contributions of non-monetary assets to an associate or a joint venture to the extent of the interest attributable to the other equity holders in the associate or joint ventures. IFRS 10 requires full profit or loss recognition on the loss of control of the subsidiary. IAS 28 was amended so that the gain or loss resulting from the sale or contribution of assets that constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized in full.

IFRS 10 was also amended so that the gains or loss resulting from the sale or contribution of a subsidiary that does not constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized only to the extent of the unrelated investors' interests in the associate or joint venture.

B. IFRS 17 "Insurance Contracts"

IFRS 17 provides a comprehensive model for insurance contracts, covering all relevant accounting aspects (including recognition, measurement, presentation and disclosure requirements). The core of IFRS 17 is the General (building block) Model, under this model, on initial recognition, an entity shall measure a group of insurance contracts at the total of the fulfilment cash flows and the contractual service margin. The carrying amount of a group of insurance contracts at the end of each reporting period shall be the sum of the liability for remaining coverage and the liability for incurred claims.

Other than the General Model, the standard also provides a specific adaptation for contracts with direct participation features (the Variable Fee Approach) and a simplified approach (Premium Allocation Approach) mainly for short-duration contracts.

IFRS 17 was issued in May 2017 and it was amended in 2020 and 2021. The amendments include deferral of the date of initial application of IFRS 17 by two years to annual beginning on or after 1 January 2023 (from the original effective date of 1 January 2021); provide additional transition reliefs; simplify some requirements to reduce the costs of applying IFRS 17 and revise some requirements to make the results easier to explain. IFRS 17 replaces an interim Standard – IFRS 4 Insurance Contracts – from annual reporting periods beginning on or after 1 January 2023.

C. IFRS 18 "Presentation and Disclosure in Financial Statements"

IFRS 18 replaces IAS 1 Presentation of Financial Statements. The main changes are as below:

(1) Improved comparability in the statement of profit or loss (income statement)

IFRS 18 requires entities to classify all income and expenses within their statement of profit or loss into one of five categories: operating; investing; financing; income taxes; and discontinued operations. The first three categories are new, to improve the structure of the income statement, and requires all entities to provide new defined subtotals, including operating profit or loss. The improved structure and new subtotals will give investors a consistent starting point for analyzing entities' performance and make it easier to compare entities.

(2) Enhanced transparency of management-defined performance measures

IFRS 18 requires entities to disclose explanations of those entity-specific measures that are related to the income statement, referred to as management-defined performance measures.

(3) Useful grouping of information in the financial statements

IFRS 18 sets out enhanced guidance on how to organize information and whether to provide it in the primary financial statements or in the notes. The changes are expected to provide more detailed and useful information. IFRS 18 also requires entities to provide more transparency about operating expenses, helping investors to find and understand the information they need.

(d) Disclosure Initiative – Subsidiaries without Public Accountability: Disclosures (IFRS 19)

This standard permits subsidiaries without public accountability to provide reduced disclosures when applying IFRS Accounting Standards in their financial statements. IFRS 19 is optional for subsidiaries that are eligible and sets out the disclosure requirements for subsidiaries that elect to apply it.

(e) Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7

The amendments include:

(1) Clarify that a financial liability is derecognised on the settlement date and describe the accounting treatment for settlement of financial liabilities using an electronic payment system before the settlement date.
(2) Clarify how to assess the contractual cash flow characteristics of financial assets that include environmental, social and governance (ESG)-linked features and other similar contingent features.
(3) Clarify the treatment of non-recourse assets and contractually linked instruments.
(4) Require additional disclosures in IFRS 7 for financial assets and liabilities with contractual terms that reference a contingent event (including those that are ESG-linked), and equity instruments classified at fair value through other comprehensive income.

(f) Annual Improvements to IFRS Accounting Standards – Volume 11

(1) Amendments to IFRS 1
The amendments mainly improve the consistency in wording between first-time adoption of IFRS and requirements for hedge accounting in IFRS 9.

(2) Amendments to IFRS 7
The amendments update an obsolete cross-reference relating to gain or loss on derecognition.

(3) Amendments to Guidance on implementing IFRS 7
The amendments improve some of the wordings in the implementation guidance, including the introduction, disclosure of deferred difference between fair value and transaction price and credit risk disclosures.

(4) Amendments to IFRS 9
The amendments add a cross-reference to resolve potential confusion for a lessee applying the derecognition requirements and clarify the term “transaction price”.

(5) Amendments to IFRS 10
The amendments remove the inconsistency between paragraphs B73 and B74 of IFRS 10.

(6) Amendments to IAS 7
The amendments remove a reference to “cost method” in paragraph 37 of IAS 7.

(g) Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7

The amendments include:

(1) Clarify the application of the 'own-use' requirements.
(2) Permit hedge accounting if these contracts are used as hedging instruments.
(3) Add new disclosure requirements to enable investors to understand the effect of these contracts on a company's financial performance and cash flows.

The abovementioned standards and interpretations issued by IASB have not yet endorsed by FSC at the date when the Group's financial statements were authorized for issue, the local effective dates are to be determined by FSC. As the Group is still currently determining the potential impact of the new or amended standards and interpretations listed under and (c), it is not practicable to estimate their impact on the Group at this point in time. The remaining new or amended standards and interpretations have no material impact on the Group.

4. Summary of significant accounting policies

(1) Statement of compliance

The consolidated financial statements of the Group for the three-month periods ended 31 March 2025 and 2024 have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers ("the Regulations") and IAS 34 Interim Financial Reporting as endorsed and became effective by the FSC.

(2) Basis of preparation

The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments that have been measured at fair value. The consolidated financial statements are expressed in thousands of New Taiwan Dollars ("NT$") unless otherwise stated.

(3) Basis of consolidation

Preparation principle of consolidated financial statements

The Group's consolidated financial statements preparation principles are the same as the 2024 consolidated financial statements. Please refer to the Group's 2024 consolidated financial statements.

The consolidated entities are listed as follows:

Investor	Subsidiary	Main businesses	Percentage of ownership (%)		
			2025.3.31	2024.12.31	2024.3.31
The Group	AVC INTERNATIONAL CO., LTD.－ B.V.I. (AVCI－BVI)	Investment holding	100.00%	100.00%	100.00%
	CHIHUNG INTERNATIONAL LTD. (CHIHUNG)	Investment holding	100.00%	100.00%	100.00%
	RAYNEY INTERNATIONAL LTD. (RAYNEY)	Trade	100.00%	100.00%	100.00%
	MERIT TRADING CORPORATION (MERIT)	Trade	100.00%	100.00%	100.00%
	AVC AMERICA, INC. (AVCA)	Trade	100.00%	100.00%	100.00%
	AVC INTERNATIONAL (SAMOA) CO., LTD. (AVCI(SAMOA))	Trade	100.00%	100.00%	100.00%
	JADS CORPORATION (HK) LTD. (JADS)	Trade	100.00%	100.00%	100.00%

Investor	Subsidiary	Main businesses	Percentage of ownership (%)		
			2025.3.31	2024.12.31	2024.3.31
	AVC INTERNATIONAL CO., LTD.－ SAMOA (AVCI－SAMOA)	Trade	100.00%	100.00%	100.00%
	HUNG YE INVESTMENT CO., LTD. (HUNGYE)	Investment holding	100.00%	100.00%	100.00%
	D-MAX TECHNOLOGY CO., LTD. (D-MAX)	Sales and manufacture of electronic parts and related products	100.00%	100.00%	100.00%
	FOSITEK CORP. (FST)	Sales and manufacture of electronic parts and related products	16.87%	16.87%	16.87%
	AVC EUROPE TECHNOLOGY GMBH (AVCEU)	Trade	100.00%	100.00%	100.00%
	AVC TECHNOLOGY (VIETNAM) COMPANY LIMITED. (AVC(VN))	Sales and manufacture of electronic products	100.00%	100.00%	100.00%
AVCI－BVI	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD. (AVCSZ)	Sales and manufacture of electronic products	100.00%	100.00%	100.00%
	MACE TECH CORP. (MACE)	Trade	100.00%	100.00%	100.00%
	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD. (AVCCD)	Sales and manufacture of computers, related parts and accessories	100.00%	100.00%	100.00%
	AVC OPTICS CORP. (AVCOC)	Investment holding	100.00%	100.00%	100.00%
MACE	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. (AVCDG)	Manufacture, process and sales of electronic products	100.00%	100.00%	100.00%
AVCDG	AVC PRECISION, CO., LTD.	Manufacture, sales of electronic products	100.00%	100.00%	100.00%
AVCOC	AVC OPTICS (WUHAN) CORP. (AVCWH)	Sales and manufacture of computers, related parts and accessories	100.00%	100.00%	100.00%
AVCWH	WUHAN ASIA VITAL COMPONENTS CO.,LTD. (AVCWN)	Trade	100.00%	100.00%	100.00%
CHIHUNG	ASIA VITAL COMPONENTS (CHINA) CO., LTD. (AVCCN)	Sales and manufacture of electronic products	100.00%	100.00%	100.00%

Investor	Subsidiary	Main businesses	Percentage of ownership (%)		
			2025.3.31	2024.12.31	2024.3.31
AVCCN	BEIJING AVC TECHNOLOGY RESEARCH CENTER CO., LTD. (AVCBJ)	Maintenance, research and development of electronic products	100.00%	100.00%	100.00%
D-MAX	WUCHIDA INTERNATIONAL CO., LTD. (WUCHIDA)	Investment holding	100.00%	100.00%	100.00%
WUCHIDA	D-Max INTERNATIONAL CO., LIMITED (D-Max)	Investment holding	100.00%	100.00%	100.00%
D-Max	(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	Sales and manufacture of electronic and photographic equipment	100.00%	100.00%	100.00%
FSD	MARKETHILL INVESTMENTS LIMITED (MARKETHILL)	Investment holding	100.00%	100.00%	100.00%
	FOSITEK (VIET NAM) COMPANY LIMITED	Sales and manufacture of rails and hinges	100.00%	100.00%	100.00%
	FOSITEK AMERICA, INC.	Sales of hinges	100.00% (Note 1)	100.00% (Note 1)	—
MARKETHILL	SHENZHEN FOSITEK TELECOM CO.,LTD.	Sales and manufacture of rails, hinges and metal stamping tooling	100.00%	100.00%	100.00%
FIRST DOME CORP	DONGGUAN FOSITEK TELECOME CO.,LTD.	Sales and manufacture of hinges	100.00%	—	100.00%

Note 1: FST, a subsidiary of the Company, invested in the establishment of the Company in May of 2024

Although the percentage of ownership interests in FST is less than 50%, the Group determined that it has control over FST. This is due to a combination of factors : the Group remains the single largest shareholder of FST since the increase of the investment in September 2014, the Group could obtain proxies to achieve relative majority in the absence of a contractual arrangement in place; and the ability of the Company to appoint or approve the key management personnel of FST who have the ability to direct the relevant activities.

The financial statements of part of the consolidated subsidiaries listed above had not been reviewed by auditors. As of MARCH 31, 2025and 2024, the related assets of the subsidiaries which were unaudited by auditors amount to $24,601,426 thousand and $14,957,250 thousand respectively, and the related liabilities amount to $15,694.386 thousand and $8,425,098 thousand, respectively. The comprehensive income of these subsidiaries amount to $381,993 thousand and $66,174 thousand for the three-month periods ended MARCH 31, 2025 and 2024, respectively.

(4) Basis of consolidationt

The accounting policies adopted by the Group in the consolidated financial statements from January 1 to MARCH 31, 2025 and 2024 are the same as the consolidated financial statements of 2024. For the summary of other important accounting policies, please refer to the Group’s 2024 consolidated financial statements.

5. Significant accounting judgements, estimates and assumptions

The major sources of significant accounting judgments, estimates and assumptions that are used in the Group's consolidated financial statements for the period from January 1 to March 31 2025 and 2024are the same as the 2024 consolidated financial statements. Please refer to the Group's 2024 consolidated financial statements.

6. Contents of significant accounts

(1) Cash and cash equivalents

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Cash on hand and demand deposits	$28,964,072	$24,253,788	$23,044,371
Time deposits	5,494,473	5,669,720	5,760,066
Securities purchased under resell agreements	33,388	—	33,164
Total	$34,491,933	$29,923,508	$28,837,601

(2) Financial assets measured at amortized cost, current

Current:	31 Mar 2025	31 Dec 2024	31 Mar 2024
Bank deposits	$3,964,515	$2,075,672	$2,194,604
Noncurrent:			
Bond	33,138	32,719	31,934
Total	$3,997,653	$2,108,391	$2,226,538

The Group classified certain financial assets as financial assets measured at amortized cost. Please refer to Note 8 for more details on financial assets measured at amortized cost under pledge and Note 12 for details on credit risk and assessment of impairment loss.

(3) Notes receivable, net

A.

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Notes receivable	$1,463,569	$1,307,474	$840,216
Less: loss allowance	(3,186)	(1,837)	(2,568)
Total	$1,460,383	$1,305,637	$837,648

B. Notes receivables arised from operating activities and were not pledged.

C. The Group follows the requirement of IFRS 9 to assess the impairment. The Group measures the loss allowance of its note receivables at an amount equal to lifetime expected credit losses. The movement in the provision for impairment of note receivables is as follows:

Movement of the loss allowance table:

	Loss allowance
As of 1 Jan 2025	$1,837
Charge for the current period	1,293
Foreign exchange adjustments	56
As of 31 Mar 2025	$3,186
As of 1 Jan 2024	$1,459
Charge for the current period	1,070
Foreign exchange adjustments	39
As of 31 Mar 2024	$2,568

(4) Accounts receivable, net

A.

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Account receivables	$3,700,686	$6,730,156	$4,819,016
Less: loss allowance	(252,465)	(268,825)	(196,817)
Total	$3,448,221	$6,461,331	$4,622,199

B. Accounts receivables were not pledged.

C. Trade receivables are generally on 90-150 day terms. The total carrying amount as of March 31, 2025, December 31, 2024 and March 31, 2024 were $3,700,686 thousand, $6,730,156 thousand and $4,819,016 thousand, respectively. The Group follows the requirement of IFRS 9 to assess the impairment, measure the loss allowance of its trade receivables at an amount equal to lifetime expected credit losses, condsider the grouping of note receivables by counterparties' credit rating, by geographical region and by industry sector, and its loss allowance is recognized based on expected loss ratio, details are as follow.

	Neither past due nor impaired	Past due but not impaired			Total
		31~90 days	91~180 days	>=181 days	
31Mar 2025					
Gross carrying amount	$3,644,574	$19,533	$5,241	$31,338	$3,700,686
Loss ratio	0%～5%	1%～10%	5%～20%	50%～100%	
Lifetime expected credit losses	220,670	195	262	31,338	252,465
Subtotal	$3,423,904	$19,338	$4,979	—	$3,448,221
31 Dec 2024					
Gross carrying amount	$6,692,112	$5,002	$108	$32,934	$6,730,156
Loss ratio	0%～5%	1%～10%	5%～20%	50%～100%	
Lifetime expected credit losses	235,835	50	6	32,934	268,825
Subtotal	$6,456,277	$4,952	$102	—	$6,461,331
31 Mar 2024					
Gross carrying amount	$4,768,159	$17,862	$475	$32,520	$4,819,016
Loss ratio	0%～5%	1%～10%	5%～20%	50%～100%	
Lifetime expected credit losses	164,094	179	24	32,520	196,817
Subtotal	$4,604,065	$17,683	$451	—	$4,622,199

D. Movement of the loss allowance table:

	Collectively impaired
As of 1 Jan 2025	$268,825
(Reversal) for the current period	(17,929)
Foreign exchange adjustments	1,569
As of 31 Mar 2025	$252,465
As of 1 Jan 2024	$209,392
(Reversal) for the current period	(14,174)
Foreign exchange adjustments	1,599
As of 31 Mar 2024	$196,817

E. The Group entered into a factoring agreement with the following banks to sell its accounts receivable. Under the agreement, the Group is not obligated to bear the default risk of the transferred accounts receivable but is liable for the losses incurred on any business dispute. The Group does not have any continuing involvement in the transferred accounts receivable. Thus, the Group derecognized the transferred accounts receivable.

As of 31 March 2025, 31 December 2024 and 31 March 2024, other receivables from banks incurred by accounts receivable factoring amounted to $396,919 thousand, $309,879 thousand and $520,884 thousand, respectively.

As of 31 March 2025, 31 December 2024 and 31 March 2024, the relevant information of accounts receivable factored and derecognised by the Group is as follows:

(a) 31 March 2025:

The Factor (Transferee)	Interest Rate (%)	Accounts receivable factoring not yet due (in thousands)	Amount received (in thousands)	Retention (recognized as other receivables) (in thousands)	Credit Limit (in thousands)
E.SUN	–	$11,954	–	$11,954	$100,000
CTBC	–	–	–	–	12,000
Total		$11,954	–	$11,954	$112,000

(b) 31 December 2024:

The Factor (Transferee)	Interest Rate (%)	Accounts receivable factoring not yet due (in thousands)	Amount received (in thousands)	Retention (recognized as other receivables) (in thousands)	Credit Limit (in thousands)
E.SUN	—	$9,452	—	$9,452	$100,000
CTBC	—	—	—	—	12,000
Total		$9,452	—	$9,452	$112,000

(c) 31 March 2024:

The Factor (Transferee)	Interest Rate (%)	Accounts receivable factoring not yet due (in thousands)	Amount received (in thousands)	Retention (recognized as other receivables) (in thousands)	Credit Limit (in thousands)
E.SUN	—	$14,962	—	$14,962	$100,000
CTBC	—	1,316	—	1,316	20,000
Total		$16,278	—	$16,278	$120,000

(5) Other receivables and other receivables-related parties

A.

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Tax refund receivable	$106,795	$79,345	$13,830
Other receivables	600,214	469,435	651,259
Less: loss allowance	(16,641)	(14,981)	(16,857)
Subtotal	690,368	533,799	648,232
Other receivables－related parties	3,929	5,681	5,514
Total	$694,297	$539,480	$653,746

B. The Group follows the requirement of IFRS 9 to assess the impairment. The Group measures the loss allowance of its other receivables at an amount equal to lifetime expected credit losses, condsiders the grouping of note receivables by counterparties' credit rating, by geographical region and by industry sector and its loss allowance is recognized based on expected loss ratio, details are as follow. Please refer to Note 12 for more details on credit risk management.

C. Movement of the loss allowance table:

	Collectively impaired
As of 1 Jan 2025	$14,981
Charge for the current period	1,453
Foreign exchange adjustments	207
As of 31 Mar 2025	$16,641
As of 1 Jan 2024	$16,622
(Reversal) for the current period	52
Foreign exchange adjustments	183
As of 31 Mar 2024	$16,857

(6) Inventories

A.

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Raw materials	$5,673,659	$5,321,602	$3,473,287
Work in progress	3,339,667	3,058,229	1,765,694
Finished goods	30,571,235	25,017,514	13,284,946
Total	$39,584,561	$33,397,345	$18,523,927

B. Expenses and losses incurred on inventories for the three-month periods ended March 31 2025 and 2024 were as follows:

	For the three-month periods ended March 31	
	2025	2024
Cost of inventories sold	$16,443,707	$11,554,398
(Profit) loss on inventory valuation	777,246	338,539
Loss on disposal of Inventory	84,038	43,368
Cost of goods sale	$17,304,991	$11,936,305

C. No inventories were pledged.

(7) Prepayments

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Payment in advance	$811,015	$671,009	$529,616
Other prepaid expenses	88,732	80,500	88,511
Total	$899,747	$751,509	$618,127

(8) Financial assets at fair value through other comprehensive income, noncurrent

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Debt instrument investments measured at fair value through other comprehensive income – Non-current:			
Listed companies stocks	$308,223	$368,257	–
Unlisted companies stocks	127,516	125,406	$161,236
Total	$435,739	$493,663	$161,236

Financial assets at fair value through other comprehensive income were not pledged.

(9) Investments accounted for under the equity method

A. The following table lists the investments in associates of the Group:

Investees	31 Mar 2025 Carrying amount	31 Mar 2025 Percentage of ownership (%)	31 Dec 2023 Carrying amount	31 Dec 2023 Percentage of ownership (%)	31 Mar 2024 Carrying amount	31 Mar 2024 Percentage of ownership (%)
Investments in associates:						
ZIMAG TECHNOLOGY CO., INC. (Note 1)	$53,193	9.53%	$51,803	9.53%	$50,866	9.53%
FURUKAWA AVC ELECTRONICS (SUZHOU) CO., LTD.	249,435	30.00%	203,406	30.00%	187,398	30.00%
ZHUZHOU CRRC-AVC THERMAL TECHNOLOGY CO., LTD.	134,892	25.00%	126,745	25.00%	113,233	25.00%
KEY APPLICATION TECHNOLOGY CO., LTD. (Note 2)	—	16.31%	—	16.31%	—	16.31%
PARAGON SEMICONDUCTOR LIGHTING TECHNOLOGY CO., LTD.	39,887	40.00%	39,171	40.00%	43,590	40.00%
DINGDAO ZHILIAN (BEILJING) (Note 3)	126,743	12.50%	215,683	12.50%	—	—
Total	$604,150		$636,808		$395,087	

Note 1: The Group evaluated and concluded that it has significant influence over Innovision, thus, this investment of the Group used the equity method for evaluation.

Note 2: The Group evaluated and concluded that it has significant influence over Innovision, thus, this investment of the Group used the equity method for evaluation

Note 3: The Group evaluated and concluded that it has significant influence over Innovision, thus, this investment of the Group used the equity method for evaluation

Investments accounted for using the equity method of the Company and its subsidiaries, were $604,150 thousand, $636,808 thousand and$395,087 thousand as of 31 March 2025, 31 December 2024 and 31 March 2024, respectively. For the three-month periods ended 31 March 2025 and 2024 , the related shares of investment income (loss) from the associates were ($44,292) thousand and $25,722 thousand , respectively. The related shares of other comprehensive income from the associates were $2,626 thousand and ($3,854) thousand, which were based solely on the financial reports of other independent accountants.

None of the aforementioned associates were pledged.

B. Financial information of associates:

There is no individually significant associate for the Group. When an associate is a foreign operation, and the functional currency of the foreign entity is different from the Group, an exchange difference arising from translation of the foreign entity will be recognized in other comprehensive income (loss).

The aggregate financial information of the Group's investments in its joint ventures is as follows:

	For the three-month periods ended March 31	
	2025	2024
Net income	($44,292)	$25,722
Other comprehensive (loss) income	2,626	(3,854)
Total comprehensive income	($41,666)	$21,868

(10) Property, plant and equipment

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Owner occupied property, plant and equipment	$14,707,608	$13,805,248	$11,715,885

A. Owner occupied property, plant and equipment

	Land	Buildings	Machinery and equipment	Molding equipment	Other facilities	Construction in progress and equipment awaiting examination	Total
Cost:							
As of 1 Jan 2025	$167,151	$3,570,716	$10,094,089	$1,161,925	$5,411,504	$2,543,343	$22,948,728
Additions	—	537,009	446,577	163,139	494,998	(282,297)	1,359,426
Disposals	—	—	(30,493)	(8,227)	(91,370)	—	(130,090)
Transfers and reclassifications	—	(50,837)	—	—	—	—	(50,837)
Exchange differences	—	58,610	191,983	13,506	99,264	29,427	392,790
As of 31 Mar 2025	$167,151	$4,115,498	$10,702,156	$1,330,343	$5,914,396	$2,290,473	$24,520,017
Depreciation and impairment:							
As of 1 Jan 2025	—	$940,004	$4,294,397	$876,301	$3,032,778	—	$9,143,480
Depreciation	—	31,750	262,357	70,080	255,623	—	619,810
Impairment loss	—	—	12,821	—	—	—	12,821
Disposals	—	—	(11,901)	(6,343)	(74,758)	—	(93,002)
Transfers and reclassifications	—	(22,861)	—	—	—	—	(22,861)
Exchange differences	—	17,206	71,527	15,364	48,064	—	152,161
As of 31 Mar 2025	—	$996,099	$4,629,201	$955,402	$3,261,707	—	$9,812,409

	Land	Buildings	Machinery and equipment	Molding equipment	Other facilities	Construction in progress and equipment awaiting examination	Total
Cost:							
As of 1 Jan 2024	$167,151	$3,808,129	$8,471,565	$925,344	$4,313,056	$1,509,626	$19,194,871
Additions	—	—	256,447	12,279	185,124	168,206	622,056
Disposals	—	—	(66,301)	(10,787)	(38,568)	—	(115,656)
Transfers and reclassifications	—	(24,963)	—	—	—	—	(24,963)
Exchange differences	—	74,519	177,739	15,621	68,361	24,774	361,014
As of 31 Mar 2024	$167,151	$3,857,685	$8,839,450	$942,457	$4,527,973	$1,702,606	$20,037,322
Depreciation and impairment:							
As of 1 Jan 2024	—	$1,173,509	$3,550,303	$712,591	$2,408,368	—	$7,844,771
Depreciation	—	29,252	209,588	43,092	177,868	—	459,800
Impairment loss	—	—	—	—	—	—	—
Disposals	—	—	(55,649)	(10,787)	(30,686)	—	(97,122)
Transfers and reclassifications	—	(6,502)	—	—	—	—	(6,502)
Exchange differences	—	27,908	49,623	12,732	30,227	—	120,490
As of 31 Mar 2024	—	$1,224,167	$3,753,865	$757,628	$2,585,777	—	$8,321,437
Net carrying amount as of:							
31 Mar 2025	$167,151	$3,149,399	$6,072,955	$374,941	$2,652,689	$2,290,473	$14,707,608
31 Dec 2024	$167,151	$2,630,712	$5,799,692	$285,624	$2,378,726	$2,543,343	$13,805,248
31 Mar 2024	$167,151	$2,633,518	$5,085,585	$184,829	$1,942,196	$1,702,606	$11,715,885

B. The Group has evaluated the value of some machinery and equipment has been impaired, and impairment losses are recognized amounted to NT$12,821 thousand for the years ended 31 March 2025. The recoverable amount is the difference between fair value and disposal cost, this fair value measurement is categorized under Level 3.

C. lease refer to Note 8 for more details on property, plant and equipment under pledge.

(11) Investment property

Investment property includes the Group's own occupied investment property and the investment property held by the Group with the right-of-use assets. The Group enters into commercial property leasing contracts for its own investment property with a leasing period ranging from 1 to 10 years. The lease contract includes provisions for adjusting the rent based on the annual market environment.

	Land	Buildings	Total
Cost：			
As of 1 Jan 2025	$131,910	$247,845	$379,755
Additions	—	—	—
Transfers and reclassifications	—	50,837	50,837
Exchange differences	—	2,412	2,412
As of 31 Mar 2025	$131,910	$301,094	$433,004
As of 1 Jan 2024	$8,769	$191,772	$200,541
Additions	—	—	—
Transfers and reclassifications	—	24,963	24,963
Exchange differences	—	1,755	1,755
As of 31 Mar 2024	$8,769	$218,490	$227,259
Depreciation and impairment:			
As of 1 Jan 2025	—	$110,992	$110,992
Depreciation	—	1,503	1,503
Transfers and reclassifications	—	22,861	22,861
Exchange differences	—	584	584
As of 31 Mar 2025	—	$135,940	$135,940
As of 1 Jan 2024	—	$94,903	$94,903
Depreciation	—	988	988
Transfers and reclassifications	—	6,502	6,502
Exchange differences	—	387	387
As of 31 Mar 2024	—	$102,780	$102,780
Net carrying amount as at:			
As of 31 Mar 2025	$131,910	$165,154	$297,064
As of 31 Dec 2024	$131,910	$136,853	$268,763
As of 31 Mar 2024	$8,769	$115,710	$124,479

	For the three-month periods ended March 31	
	2025	2024
Rental income from investment property	$8,320	$5,962
Less: Direct operating expenses from Investment property generating rental income	(2,071)	(1,545)
Total	$6,249	$4,417

Please refer to Note 8 for more details on investment property under pledge.

The investment property held by the Group is industrial land and buildings, and the fair value is equivalent to the carrying value.

(12) Intangible assets

	Computer software	Patents	License fee	Goodwill	Total
Cost:					
As of 1 Jan 2025	$567,908	$5,313	$25,679	$7,107	$606,007
Addition	2,960	－	－	－	2,960
Disposals	(2,586)	－	(15,406)	－	(17,992)
Transfers and reclassifications	－	－	－	－	－
Exchange differences	7,212	2	－	－	7,214
As of 31 Mar 2025	$575,494	$5,315	$10,273	$7,107	$598,189
As of 1 Jan 2024	$494,922	$5,185	$25,679	$7,107	$532,893
Addition	10,262	95	－	－	10,357
Disposals	－	－	－	－	－
Transfers and reclassifications	－	－	－	－	－
Exchange differences	4,047	2	－	－	4,049
As of 31 Mar 2024	$509,231	$5,282	$25,679	$7,107	$547,299
Amortization and impairment:					
As of 1 Jan 2025	$402,016	$5,313	$22,904	$7,107	$437,340
Amortization	12,646	－	219	－	12,865
Disposals	(2,586)	－	(15,406)	－	(17,992)
Transfers and reclassifications	－	－	－	－	－
Exchange differences	4,654	2	－	－	4,656
As of 31 Mar 2025	$416,730	$5,315	$7,717	$7,107	$436,869

	Computer software	Patents	License fee	Goodwill	Total
As of 1 Jan 2024	$322,001	$5,185	$22,026	$7,107	$356,319
Amortization	19,760	95	221	—	20,076
Disposals	—	—	—	—	—
Transfers and reclassifications	—	—	—	—	—
Exchange differences	1,892	2	—	—	1,894
As of 31 Mar 2024	$343,653	$5,282	$22,247	$7,107	$378,289
Net carrying amount as at:					
31 Mar 2025	$158,764	—	$2,556	—	$161,320
31 Dec 2024	$165,892	—	$2,775	—	$168,667
31 Mar 2024	$165,578	—	$3,432	—	$169,010

Amortization expense of intangible assets under the statement of comprehensive income:

	For the three-month periods ended March 31	
	2025	2024
Operating costs	$2,985	$2,248
Operating expenses	$9,880	$17,828

(13) Other non-current assets

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Advance payments in equipments	$4,489,506	$3,645,682	$1,753,847
Refundable deposits	282,009	276,031	199,275
Other advance	129,803	128,789	128,789
Other non-current assets - other	3,813	4,237	5,548
Total	$4,905,131	$4,054,739	$2,087,459

Please refer to Note 8 for more details on other non-current assets under pledge.

(14) Short-term borrowings

A.

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Unsecured bank loans	$10,225,347	$9,585,252	$5,894,360

B. Interest rate ranges are within 1.7300%~5.3500% , 1.7000%~5.7700% and 1.7740%~6.7000% as of 31 March 2025, 31 December 2024 and 31 March 2024, respectively.

C. As of 31 March 2025, 31 December 2024 and 31 March 2024, unused short-term lines of credit were $17,124,786 thousand, $16,785,825 thousand and $15,547,695 thousand, respectively.

(15) Other payables

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Salaries and bonus	$3,587,452	$3,421,320	$2,598,251
Employee's compensation and remuneration of directors	741,941	539,700	459,627
Dividend payable	4,332,848	—	2,996,600
Others	4,296,711	3,963,905	3,349,354
Total	$12,958,952	$7,924,925	$9,403,832

(16) Corporate Bonds payable

	31 Mar 2025	31 Dec 2024	31 Mar 2024	Collateral
5 year secured bonds - issued at par value. Issued in August 2020. Interest at 0.62%, bullet repayment, payable annually.	$2,400,000	$2,400,000	$2,400,000	Bank guarantee
Less: current portion	(2,400,000)	(2,400,000)	—	
Ending balance	—	—	$2,400,000	

The issuance of the above corporate bonds payable is to repay existing loans and expand working capital, the Company entered into a syndicated credit facility agreement with 9 banks by E.SUN Commercial Bank, Taiwan Cooperative Bank, Hua Nan Commercial Bank, Bank of Taiwan, Land Bank of Taiwan, Mega International Commercial Bank, The Shanghai Commercial & Savings Bank, First Commercial Bank and CTBC Bank for a NT$2,424,000 thousand credit line.

(17) Long-term borrowings

	31 Mar 2025	31 Dec 2024	31 Mar 2024	Redemption
Unsecured Long-Term Loan from Taiwan Cooperative Bank	$75,000	$93,750	$150,000	Effective 25 Mar 2022 to 24 Mar 2026. Four-year loan: principal is repaid in 16 quarterly payments with monthly interest payments.
Unsecured Long-Term Loan from Taiwan Cooperative Bank	250,000	281,250	375,000	Effective 9 Feb 2023 to 8 Feb 2027. Four-year loan: principal is repaid in 16 quarterly payments with monthly interest payments.
Unsecured Long-Term Loan from Taiwan Cooperative Bank	425,000	450,000	—	Effective 28 May 2024 to 27 May 2029. Five-year loan: principal is repaid in 20 quarterly payments with monthly interest payments.
Unsecured Long-Term Loan from Export-Import Bank of the Republic of China	187,500	187,500	250,000	Effective 21 Dec 2021 to 21 Dec 2027. Six-year loan: interest-only payment for 30 months. Principal is repaid with monthly interest payments.

	31 Mar 2025	31 Dec 2024	31 Mar 2024	Redemption
Unsecured Long-Term Loan from E. Sun Bank	$375,000	$437,500	$500,000	Effective 25 Aug 2023 to 25 Aug 2026. Three-year loan: One-year grace period,principal is amortized on a quarterly basis, and interest is paid on a monthly basis.
Unsecured Long-Term Loan from Land Bank of Taiwan	—	—	174,999	Effective 22 Dec 2022 to 22 Dec 2025. Three-year loan: principal is repaid in monthly payments with interest.
Unsecured Long-Term Loan from Export-Import Bank of the Republic of China	600,000	600,000	—	Effective 16 Oct 2024 to 16 Oct 2030. Six-year loan: interest-only payment for 30 months. Principal is repaid with monthly interest payments.
Unsecured Long-Term Loan from Export-Import Bank of the Republic of China	673,750	673,750	770,000	Effective 11 Apr 2022 to 11 Apr 2028. Six-year loan: interest-only payment for 30 months. Principal is repaid with monthly interest payments.
Unsecured Long-Term Loan from Taiwan Business Bank	156,250	187,500	281,250	Effective 17 June 2022 to 17 June 2026. Four-year loan: principal is repaid in monthly payments with monthly interest payments.
Unsecured Long-Term Loan from HSBC Commercial Bank	—	—	200,000	2-year recycled with each loan The actual credit line is based on the dial date, and the actual credit line is annual. Review in June, interest is paid on a monthly basis, and the interest is calculated on a daily basis. Interest is accrued, and the principal can be repaid at maturity.
Unsecured Long-Term Loan from DBS Bank	160,000	160,000	160,000	Revolving line are two years,every loans can’t be over six months.The two-year limit is based on the initial draw-down date. The actual credit line has no maturity date.
Unsecured Long-Term Loan from DBS Bank	200,000	200,000	—	Revolving line are two years,every loans can’t be over six months.The two-year limit is based on the initial draw-down date. The actual credit line has no maturity date.

	31 Mar 2025	31 Dec 2024	31 Mar 2024	Redemption
Unsecured Long-Term Loan from Hua Nan Bank	$200,000	$200,000	$200,000	Effective 16 Oct 2023 to 16 Oct 2026. Three-year loan: principal is repaid in monthly payments with monthly interest payments.
Unsecured Long-Term Loan from Land Bank of Taiwan	291,667	—	—	Effective 18 Feb 2025 to 18 Feb 2028. Three-year loan: principal is repaid in monthly payments with interest.
Unsecured Long-Term Loan from Far Eastern International Bank	550,000	550,000	—	Effective 10 Dec 2024 to 10 Dec 2029. Five-year loan: interest-only payment for 24 months. Principal is repaid with monthly interest payments.
Unsecured Long-Term Loan from Shanghai Commercial & Savings Bank	218,565	231,791	285,786	Effective 24 Oct 2022 to 23 Oct 2027. Five-year loan: principal is amortized on a quarterly basis.
Unsecured Long-Term Loan from Taipei Fubon Bank	211,942	240,375	304,838	Effective 20 Jul 2023 to 19 Jul 2026. Three-year loan: One-year grace period, principal is amortized on a quarterly basis.
Subtotal	4,574,675	4,493,416	3,651,873	
Less: Due within one year	(1,250,774)	(1,144,621)	(886,573)	
Total	$3,323,901	$3,348,795	$2,765,300	
Range of interest rates	1.6083%～5.3100%	1.6048%～5.6600%	1.6400%～6.2000%	

(18) Long-term deferred revenue

Government grants were as follows:

	For the three-month periods ended March 31	
	2025	2024
Beginning balance	$661,136	$665,737
Released to the statement of comprehensive income	(7,052)	(6,824)
Exchange differences	13,766	12,744
Ending balance	$667,850	$671,657

Government grants have been received for the purchase of certain items of property, plant and equipment.

(19) Post-employment benefits

A. Defined contribution plan

Expenses under the defined contribution plan for the three-month periods ended 31 March 2025 and 2024 are $9,692 thousand and $8,811 thousand, respectively.

B. Defined benefits plan

Costs under the defined benefits plan for the three-month periods ended 31 March 2025 and 2024 are $813 thousand and $663 thousand, respectively.

(20) Equities

A. Common stock

As of 31 March 2025, 31 December 2024 and 31 March 2024, the Group's authorized capital was $6,000,000 thousand, and issued $3,876,951 thousand, $3,875,535 thousand, and $3,833,101 thousand with 387,695 thousand shares, 387,554 thousand shares, and 383,310 thousand shares each at a par value of $10, respectively. Each share has one voting right and a right to receive dividends.

The Company has delivered 142 thousand ordinary shares with a par value of NT$10 per share due to the exercise of stock options by employees, and as of March 31, 2025, Relevant regulators' approvals have been obtained and related registration processes have been completed.

Issued 472 new shares for the nine months ended March 31, 2025, at par value of NT$10 for exercising employee stock options. The aforementioned newly issued shares (NT$23,317 thousand in the amount) were not yet registered and therefore were classified as capital collected in advance as of March 31, 2025.

B. Additional paid-in capital

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Share premium	$825,481	$1,982,987	$1,814,388
Difference between consideration and carrying amount of subsidiaries acquired or disposed	83,185	83,185	83,185
Changes in ownership interests in subsidiaries	253,379	253,379	253,379
Donated assets received	4,027	3,849	3,849
Premium from merger	443,730	443,730	443,730
Employee stock option	916,769	755,982	755,981
Share options of convertible bonds	23,292	23,292	23,292
Total	$2,549,863	$3,546,404	$3,377,804

According to the Company Act, the capital reserve shall not be used except for making good the deficit of the company. When a company incurs no loss, it may distribute the capital reserves related to the income derived from the issuance of new shares at a premium or income from endowments received by the company. The distribution could be made in cash or in the form of dividend shares to its shareholders in proportion to the number of shares being held by each of them.

C. Retained earnings and dividend policies

According to the Company's Articles of Incorporation, current year's earnings, if any, shall be distributed in the following order:

(a) Payment of all taxes and dues;

(b) Offset prior years' operation losses;

(c) Set aside 10% of the remaining amount after deducting items (a) and (b) as legal reserve, except for when accumulated legal reserve has reached total authorized capital.

(d) Set aside or reverse special reserve in accordance with law and regulations; and

(e) The distribution of the remaining portion, if any, will be recommended by the Board of Directors and resolved in the shareholders' meeting.

(f) According to Paragraph 5, Article 240 of the Company Act, the resolution authorizing a majority vote at a meeting of Board of Directors attended by two-thirds of the total number of directors shall, in the form of the distribution of dividends and dividends or all or part of the legal reserves and capital reserves provided for in Paragraph 1, Article 241 of the Companies Act, shall be paid in cash and shall be reported to the shareholders' meeting.

The policy of dividend distribution should reflect factors such as the current and future development plan, investment environment, fund requirements, domestic and international competition as well as the interest of the shareholders. A percentage of no less than 5% of the distributable profits of the accounting period shall be distributed as shareholders' dividends annually. When the accumulated distributable profits are less than 10% of our paid-up capital, we will no longer be required to make allowances for allocation. Shareholders' dividends could be paid in the form of shares or cash. Accordingly, at least 10% of the dividends must be paid in the form of cash.

According to the Company Act, the Company needs to set aside an amount to legal reserves unless where such legal reserve amounts to the total authorized capital. The legal reserve can be used to make good the deficit of the Company. When the Company incurs no loss, it may distribute the portion of legal reserves that exceeds 25% of the paid-in capital by issuing new shares or by cash in proportion to the number of shares being held by each of the shareholders.

Following the adoption of TIFRS, the FSC on 31 March 2021 issued Order No. Financial-Supervisory-Securities-Corporate-1090150022, which sets out the following provisions for compliance: On a public company's first-time adoption of the TIFRS, for any unrealized revaluation gains and cumulative translation adjustments (gains) recorded to shareholders' equity that the company elects to transfer to retained earnings by application of the exemption under IFRS 1, the company shall set aside an equal amount of special reserves. Following a company's adoption of the TIFRS for the preparation of its financial reports, when distributing distributable earnings, it shall set aside to special reserves, from the profit/loss of the current period and the undistributed earnings from the previous period. The amount should equal to "other net deductions from shareholders' equity for the current fiscal year, provided that the company has already set aside special reserves according to the requirements in the preceding point, it shall set aside supplemental special reserve based on the difference between the amount already set aside and other net deductions from shareholders' equity. For any subsequent reversal of other net deductions from shareholders' equity, the amount reversed may be distributed.

As of 1 January 2025 and 2024, special reserve set aside for the first-time adoption of TIFRS amounts to $95,481 thousand. Furthermore, the Group has not reversed special reserve for the three-month periods ended 31 March 2025 and 2024 as results of the no use, disposal or reclassification of related assets. As of 31 March 2025 and 2024, special reserve set aside for the first-time adoption of TIFRS amounts to $95,481 thousand.

Details of the 2025 and 2024 earnings distribution and dividends per share as approved and resolved by the shareholders' meeting on 12 March 2025 and 14 June 2024, respectively, are as follows:

	Appropriation of earnings		Dividend per share (NT$)	
	2024	2023	2024	2023
Legal reserve	$818,601	$530,198		
Special reserve	(842,353)	331,830		
Common stock -cash dividend	2,713,866	1,916,551	$7	$4.97

The Board of Directors' meeting and shareholders' meeting on 12 March 2025 and 14 June 2024 resolved to distribute $1,163,085 thousand and $766,620 thousand from capital surplus to shareholders in the form of cash. Shareholders are entitled to receive $3 and $1.99 per share.

Please refer to Note 6.24 for further details on employees' compensation and remuneration to directors and supervisors.

D. Non-controlling interests

	For the three-month periods ended March 31	
	2025	2024
Beginning balance	$4,602,241	$3,817,401
Profit attributable to non-controlling interests	296,345	186,161
Other comprehensive income, attributable to non-controlling interests, net of tax:		
Exchange differences resulting from translating the financial statements of a foreign operation	62,790	40,910
(Decreasing) in non-controlling interests	(455,897)	(313,429)
Ending balance	$4,505,479	$3,731,043

(21) Share-based payment

Certain employees of the Group are entitled to share-based payments as part of their remunerations. Services are provided by the employees in return for the equity instruments granted. These plans are accounted for as equity-settled share-based payments transactions.

A. Stock option plan for employees of the parent company

On July 7, 2022, and June 29, 2023, the Parent Company issue employee share options with a total number of 14,631 units and 2,058 units. Each unit entitles an optioned to subscribe for 1,000 shares of the Company's common shares. The exercise price of the option was set at the closing price of the Company's common share on the grant date. The optionee may exercise the options in accordance with certain schedules as prescribed by the plan starting 2 years from the grant date. Settlement upon the exercise of the options will be made through the issuance of new shares by the Parent Company.

The fair value of the share options is estimated at the grant date using a binomial option pricing-model, taking into account the terms and conditions upon which the share options were granted.

The contractual term of each option granted is 10 years. There are no cash settlement alternatives. The Group does not have a past practice of cash settlement for these employee share options.

The relevant details of the aforementioned share-based payments plan were as follows:

Date of grant	Total number of share options granted (in thousands)	The number of shares that can be option each unit (share)	Exercise price of share Options ($) (Note)
July 7, 2022	$14,631	1,000	$49.4
June 29, 2023	$2,058	1,000	$146.1

Note: The exercise prices are adjusted in accordance with the plan in the event that changes to the Company's total common shares occur or when the Company pays cash dividends

The following table lists the inputs to the model used for the plan granted during January 1 to March 31,2024:

	June 29, 2023	July 7, 2022
Dividend yield(%)	—	—
Expected volatility(%)	40.36%	36.89%
Risk-free interest rate(%)	1.16%	1.2462%
Expected option life(year)	10 years	10 years
Option pricing model	Binomial option pricing model	Binomial option pricing model

The expected life of the share options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may also not necessarily be the actual outcome.

The further details of the Group first quarter of 2025 on the aforementioned share-based payments plan were as follows:

For the three-month periods ended March 31				
Stock option	Number of share options outstanding	Average exercise price of share options ($)	Fulfillment price range ($)	Average remaining contract period of share options
Outstanding at beginning of period	12,242	$49.4~146.1	—	
Granted	—	—	—	
Exercised	(472)	$49.4	$49.4	
Expired	(10)	—		
Outstanding at end of period	11,760	—		
Exercisable at end of period	11,760	—		7.26~8.24 years

The further details of the Group first quarter of 2024 on the aforementioned share-based payments plan were as follows:

For the three-month periods ended March 31				
Stock option	Number of share options outstanding	Average exercise price of share options ($)	Fulfillment price range ($)	Average remaining contract period of share options
Outstanding at beginning of period	16,689	$50~147.8	—	8.26~9.24 years
Granted	—	—		
Exercised	—	—		
Expired	—	—		
Outstanding at end of period	16,689	—	—	
Exercisable at end of period	16,689	—	—	

B. Expenses incurred on share-based payment transactions plan were shown as follows:

	For the three-month periods ended March 31	
	2025	2024
Expenses incurred on share-based payment transactions (equity-settled share-based payments transactions)	$160,788	$277,521

C. No modification or cancellation of share-based payments plan has occurred for the years ended 31 March 2025 and 2024.

(22) Operating revenues

A. Disaggregation of revenue

	For the three-month periods ended March 31	
	2025	2024
Sale of goods	$23,332,951	$15,308,688
Timing of revenue recognition:		
At a point in time	$23,332,951	$15,308,688

B. Contract balances

Contract liabilities - current

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Sale of goods	$2,116	$2,881	$876

During the period, contract liabilities significantly decreased as performance obligations are partially satisfied and $2,881 thousand included in the contract liability balance at the beginning of the period was recognized as revenue during the period.

(23) Lease

A. Group as a lessee

The Group leases various properties, including real estate such as land and buildings, machinery and equipment and office equipment. The lease terms range from 1 to 50 years.

The Group's leases effect on the financial position, financial performance and cash flows are as follow:

(a) Amounts recognized in the balance sheet

I. Right-of-use assets

The carrying amount of right-of-use assets

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Land	$860,094	$851,363	$703,597
Buildings	2,217,977	2,136,333	1,003,143
Other equipment	32,991	32,302	28,655
Total	$3,111,062	$3,019,998	$1,735,395

During the three-month period ended 31 March 2025, the Group's additions to right-of-use assets amounted to $33,772 thousand.

II. Lease liabilities

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Current	$382,175	$335,637	$271,907
Non-current	2,013,985	1,960,515	869,182
Total	$2,396,160	$2,296,152	$1,141,089

Please refer to Note 6.25(4) for the interest on lease liabilities recognized during the three-month period ended 31 March 2025 and refer to Note 12.5 Liquidity Risk Management for the maturity analysis for lease liabilities as of 31 March 2025.

(b) Amounts recognized in the statement of profit or loss

Depreciation charge for right-of-use assets

	For the three-month periods ended March 31	
	2025	2024
Land	$6,336	$4,637
Buildings	111,399	63,480
Other equipment	8,709	8,084
Total	$126,444	$76,201

(c) Income and costs relating to leasing activities

	For the three-month periods ended March 31	
	2025	2024
The expenses relating to short-term leases	$32,262	$8,300

(d) Cash outflow relating to leasing activities

During the three-month period ended 31 March 2025, the Group's total cash outflows for leases amounting to $137,526 thousand.

B. Group as a lessor (applicable to the disclosure requirement in IFRS 16)

Please refer to Note 6.11 for relevant disclosure of the Group's own occupied investment property. Leases of owned investment properties are classified as operating leases as they do not transfer substantially all the risks and rewards incidental to ownership of underlying assets.

	For the three-month periods ended March 31	
	2025	2024
Lease income for operating leases		
Income relating to fixed lease payments and variable lease payments that depend on an index or a rate	$11,621	$6,970

Please refer to Note 6.11 for relevant disclosure of property, plant and equipment for operating leases under IFRS 16. For operating leases entered by the Group, the undiscounted lease payments to be received and a total of the amounts for the remaining years as of 31 March 2025 are as follow:

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Not later than one year	$31,865	$32,951	$23,602
Later than one year and not later than five years	65,338	54,209	55,946
Later than five years	—	—	—
Total	$97,203	$87,160	$79,548

(24) Summary statement of employee benefits, depreciation and amortization expenses by function:

Function / Nature	For the three-month periods ended March 31					
	2025			2024		
	Operating costs	Operating expenses	Total amount	Operating costs	Operating expenses	Total amount
Employee benefits expense						
Salaries	$2,289,364	$952,337	$3,241,701	$1,279,269	$913,703	$2,192,972
Labor and health insurance	$199,070	$64,942	$264,012	$94,539	$45,842	$140,381
Pension	$1,073	$9,432	$10,505	$906	$8,568	$9,474
Other employee benefits expense	$59,526	$28,785	$88,311	$31,868	$20,575	$52,443
Depreciation	$641,104	$105,150	$746,254	$445,710	$91,279	$536,989
Amortization	$3,059	$10,249	$13,308	$2,268	$18,243	$20,511

According to the Company’s Articles of Incorporation, no less than 3% of profit of the current year is distributable as employees’ compensation and no higher than 2% of profit of the current year is distributable as remuneration to directors and supervisors. However, the company's accumulated losses shall have been covered. The Company may, by a resolution adopted by a majority vote at a meeting of Board of Directors attended by two-thirds of the total number of directors, have the profit distributed as employees’ compensation in the form of shares or in cash; and in addition thereto a report of such distribution is submitted to the shareholders’ meeting. Information on the board of directors’ resolution regarding the employees’ compensation and remuneration to directors and supervisors can be obtained from the “Market Observation Post System” on the website of the TWSE.

Based on the profit of the current year, the Company estimated the amounts of the employees’ compensation and remuneration to directors and supervisors for the three-month periods ended 31 March 2025 to be $124,627 thousand and $60,303 thousand, respectively. The Company estimated the amounts of employees’ compensation and remuneration to directors and supervisors for three-month periods ended 31 March 2024 to be $59,706 thousand and $28,890 thousand, respectively. The aforementioned amounts were recognized as employee benefits expense. If the Board of Directors resolves to distribute employees’ compensation in the form of stocks, the number of stocks distributed was calculated based on the closing price of the day before the Board of Directors meeting. The difference between the estimation and the resolution of the stockholder’s meeting will be recognized in profit or loss in the subsequent year.

The Company's 2024 and 2023 employee compensation and director's compensation approved by the shareholders’ meeting on 12 March 2025 and 13 March 2024 employee compensation and director's compensation reported by the shareholders' meeting of 12 March 2025 and 13 March 2024 are as follows:

	2024	2023
Employee compensation	$320,000	$215,000
Remuneration to directors and supervisors	157,000	104,296

The distribution was passed by the Board of Directors meeting held on 12 March, 2025 to distribute NT$320,000 thousand and NT$157,000 thousand in cash as employee compensation and remuneration to directors and supervisors of 2024, which has no material differences between the expense listed in the financial report of 2024.

No material differences exist between the estimated amount and the actual distribution of the employee compensation and remuneration to directors and supervisors for the year ended 31 March, 2024 and 2023.

(25) Non-operating income and expenses

A. Interest income

	For the three-month periods ended March 31	
	2025	2024
Interest income from bank deposits	$105,839	$94,666
Financial assets at amortized cost	812	908
Others	12	12
Total	$106,663	$95,586

B. Other income

	For the three-month periods ended March 31	
	2025	2024
Rental income	$11,621	$6,970
Others	307,812	271,205
Total	$319,433	$278,175

C. Other gains and losses

	For the three-month periods ended March 31	
	2025	2024
Gains (losses) on disposal of property, plant and equipment	($31,910)	($15,687)
Foreign exchange income, net	69,687	120,981
Impairment loss	(12,821)	—
Others	(9,211)	(7,985)
Total	$15,745	$97,309

D. Finance costs

	For the three-month periods ended March 31	
	2025	2024
Interest on borrowings from bank	$117,697	$89,219
Interest on corporate bonds payable	3,720	3,720
Interest on lease liabilities	16,641	9,143
Total	$138,058	$102,082

(26) Components of other comprehensive income

For the three-month period ended 31 March 2025:

	Arising during the period	Reclassification adjustments during the period	Other comprehensive income, before tax	Income tax relating to components of other comprehensive income	Other comprehensive income, net of tax
Not to be reclassified to profit or loss in subsequent periods:					
Unrealized gain from equity instruments investments measured at fair value through other comprehensive income	($58,428)	—	($58,428)	—	($58,428)
To be reclassified to profit or loss in subsequent periods:					
Exchange differences resulting from translating the financial statements of a foreign operation	617,685	—	617,685	($43,551)	574,134
Share of other comprehensive income of associates accounted for using the equity method	2,626	—	2,626	—	2,626
Total of other comprehensive income	$561,883	—	$561,883	($43,551)	$518,332

For the three-month period ended 31 March 2024:

	Arising during the period	Reclassification adjustments during the period	Other comprehensive income, before tax	Income tax relating to components of other comprehensive income	Other comprehensive income, net of tax
Not to be reclassified to profit or loss in subsequent periods:					
Unrealized gain from equity instruments investments measured at fair value through other comprehensive income	($4,631)	—	($4,631)	—	($4,631)
To be reclassified to profit or loss in subsequent periods:					
Exchange differences resulting from translating the financial statements of a foreign operation	498,398	—	498,398	($141,454)	356,944
Share of other comprehensive income of associates accounted for using the equity method	(3,854)	—	(3,854)	—	(3,854)
Total of other comprehensive income	$489,913	—	$489,913	($141,454)	$348,459

(27) Income tax

A. The major components of income tax expense are as follows:

Income tax expense recognized in profit or loss

	For the three-month periods ended March 31	
	2025	2024
Current income tax expense:	$1,278,031	$641,689
Deferred tax expense :		
Deferred tax expense relating to origination and reversal of temporary differences	(167,761)	(62,659)
Total income tax expense	$1,110,270	$579,430

B. Income tax relating to components of other comprehensive income

	For the three-month periods ended March 31	
	2025	2024
Deferred tax expense (income):		
Exchange differences resulting from translating the financial statements of foreign opreations	$43,551	$141,454
Income tax relating to components of other comprehensive income	$43,551	$141,454

C. The assessment of income tax returns

The Company's income tax returns through 2022 have been assessed and approved by the TaxAuthority.

(28) Earnings per share

	For the three-month period ended March 31 2025		
	Amount	Number of shares (shares in thousands)	Earnings per share
Basic earnings per share			
Profit attributable to ordinary equity holders of the Company (in thousand NT$)	$3,213,746	388,134	$8.28
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	—	275	
Employee share options	—	10,343	
Diluted earnings per share			
Profit attributable to ordinary equity holders of the Company (in thousand NT$)	$3,213,746	398,752	$8.06

	For the three-month period ended March 31 2024		
	Amount	Number of shares (shares in thousands)	Earnings per share
Basic earnings per share			
Profit attributable to ordinary equity holders of the Company (in thousand NT$)	$1,564,017	383,310	$4.08
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	—	109	
Employee share options	—	12,687	
Diluted earnings per share			
Profit attributable to ordinary equity holders of the Company (in thousand NT$)	$1,564,017	396,106	$3.95

7. Related party transactions

Key management personnel compensation

	For the three-month periods ended March 31	
	2025	2024
Short-term employee benefits	$9,236	$11,128
Post-employment benefits	161	314
Total	$9,397	$11,442

8. Assets pledged as security

The following table lists assets of the Group pledged as security:

Assets pledged for security	Carrying amount		
	31 Mar 2025	31 Dec 2024	31 Mar 2024
Financial assets measured at amortized cost	$3,964,515	$2,075,672	$2,194,604
Land	88,235	88,235	88,235
Buildings	78,014	106,714	119,586
Right-of-use assets	—	—	25,330
Investment property	56,359	29,021	25,020
Refundable deposits	8,500	8,500	3,500
Total	$4,195,623	$2,308,142	$2,456,275

9. Commitments and contingencies

(1) Legal claim contingency

None.

(2) The Group signed the contract of the new plant in Vietnam for opreating purpose, which has 360 million dollars not paid until 31 March 2025.

(3) Other

The Group guaranteed a deposit for customs in the amount of $2,500 thousand and $6,000 thousand from Bank of Taiwan and Taiwan Cooperative Bank, respectively.

10. Losses due to major disasters

None.

11. Significant subsequent events

None

12. Financial instruments

(1) Categories of financial instruments

Financial assets

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Financial assets at fair value through profit or loss:			
Financial assets at fair value through other comprehensive income	$435,739	$493,663	$161,236
Financial assets measured at amortized cost			
Cash and cash equivalents (excluding cash on hand)	34,467,385	29,912,550	28,814,339
Financial assets measured at amortized cost	3,997,653	2,108,391	2,226,538
Amounts receivables	5,602,901	8,306,448	6,113,593
Subtotal	$44,067,939	$40,327,389	$37,154,470
Total	$44,503,678	$40,821,052	$37,315,706

Financial liabilities

	31 Mar 2025	31 Dec 2024	31 Mar 2024
Financial liabilities at amortized cost:			
Short-term loans	$10,225,347	$9,585,252	$5,894,360
Amounts payables	45,622,061	36,808,568	28,612,537
Corporate bonds payable (including current portion)	2,400,000	2,400,000	2,400,000
Long-term loan (including current portion)	4,574,674	4,493,416	3,651,873
Lease liabilities (including current portion)	2,396,160	2,296,152	1,141,089
Total	$65,218,242	$55,583,388	$41,699,859

(2) Financial risk management objectives and policies

The Group's principal financial risk management objective is to manage the market risk, credit risk and liquidity risk related to its operating activates. The Group identifies measures and manages the aforementioned risks based on the Group's policy and risk appetite.

The Group has established appropriate policies, procedures and internal controls for financial risk management. Before entering into significant transactions, due approval process by the Board of Directors must be carried out based on related protocols and internal control procedures. The Group complies with its financial risk management policies at all times.

(3) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of the changes in market prices. Market prices comprise currency risk, interest rate risk and other price risk (such as equity risk).

In practice, it is rarely the case that a single risk variable will change independently from other risk variable, there is usually interdependencies between risk variables. However the sensitivity analysis disclosed below does not take into account the interdependencies between risk variables.

A. Foreign currency risk

The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (when revenue or expense are denominated in a different currency from the Group's functional currency) and the Group's net investments in foreign subsidiaries.

The Group has certain foreign currency receivables to be denominated in the same foreign currency with certain foreign currency payables, therefore forming a natural hedge. Furthermore, as net investments in foreign subsidiaries are for strategic purposes, they are not hedged by the Group.

The foreign currency sensitivity analysis of the possible change in foreign exchange rates on the Group's profit is performed on significant monetary items denominated in foreign currencies as at the end of the reporting period. The Group's foreign currency risk is mainly related to the volatility in the exchange rates for USD and RMB. The information of the sensitivity analysis is as follows:

(a) When NTD strengthens/weakens against USD by 1%, the profit for the three-month periods ended 31 March 2025 and 2024 is decreased or increased by $68,848 thousand and decreased or increased by $41,669 thousand, respectively.

(b) When NTD strengthens/weakens against RMB by 1%, the profit for the three-month periods ended 31 March 2025 and 2024 is decreased or increased by $74,831 thousand and increased or decreased by $21,553 thousand, respectively.

B. Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to the risk of changes in market interest rates relates primarily to bank borrowings with fixed interest rates and variable interest rates.

The Group manages its interest rate risk by having a balanced portfolio of fixed and variable loans and borrowings and entering into interest rate swaps. Hedge accounting does not apply to these swaps as they do not qualify for it.

The interest rate sensitivity analysis is performed on items exposed to interest rate risk as at the end of the reporting period. A change of 10 basis points of interest rate in a reporting period could cause the profit for the three-month periods ended 31 March 2025 and 2024 to decrease/ increase by $21,547 thousand and $19,294 thousand, respectively.

C. Equity price risk

The fair value of the Group's unlisted equity securities are susceptible to market price risk arising from uncertainties about future values of the investment securities. The Group's unlisted equity securities are classified as financial assets at fair value through other comprehensive income.

The equity price sensitivity analysis is based on fair value changes as at the end of the reporting period. For the three-month periods ended 31 March 2025 and 2024, a change of 5% in the price classified as equity instruments investments measured at fair value through other comprehensive income could cause the other comprehensive income to increase/ decrease by $21,787 thousand and $8,062 thousand, respectively.

Please refer to Note 12.8 for sensitivity analysis information of other equity instruments or derivatives that are linked to such equity instruments whose fair value measurement is categorized under Level 3.

(4) Credit risk management

Credit risk is the risk that a counterparty will not meet its obligations under a contract, leading to a financial loss. The Group is exposed to credit risk from operating activities (primarily for accounts receivables and notes receivables) and from its financing activities, including bank deposits and other financial instruments.

Credit risk is managed by each business unit subject to the Group's established policy, procedures and control relating to credit risk management. Credit limits are established for all counter parties based on their financial position, rating from credit rating agencies, historical experience, prevailing economic condition and the Group's internal rating criteria etc. Certain counter parties' credit risk will also be managed by taking credit enhancing procedures, such as requesting for prepayment or insurance.

As of 31 March 2025, 31 December 2024 and 31 March 2024, amounts receivables from top ten customers represent 64.54%, 77.30% and 75.87% of the total accounts receivables of the Group, respectively. The credit concentration risk of other accounts receivables is insignificant.

Credit risk from balances with banks, fixed income securities and other financial instruments is managed by the Group's treasury in accordance with the Group's policy. The Group only transacts with counterparties approved by the internal control procedures, which are banks and financial institutions, companies and government entities with good credit rating. Consequently, there is no significant credit risk for these counter parties.

(5) Liquidity risk management

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of cash and cash equivalents and bank borrowings. The table below summarizes the maturity profile of the Group's financial liabilities based on the contractual undiscounted payments and contractual maturity. The payment amount includes the contractual interest. The undiscounted payment relating to borrowings with variable interest rates is extrapolated based on the estimated interest rate yield curve as of the end of the reporting period.

Non-derivative financial liabilities

	< 1 year	2 to 3 years	4 to 5 years	> 5 years	Total
As of 31 March 2025					
Loans	$11,755,607	$2,426,817	$833,090	$150,793	$15,166,307
Corporate bonds payable	$2,414,880	—	—	—	$2,414,880
Amounts payables	$45,571,820	—	—	—	$45,571,820
Lease liabilities	$443,306	$653,569	$555,294	$1,027,145	$2,679,314
As of 31 December 2024					
Loans	$10,992,356	$2,542,509	$754,138	$151,455	$14,440,458
Corporate bonds payable	$2,414,880	—	—	—	$2,414,880
Amounts payables	$36,760,755	—	—	—	$36,760,755
Lease liabilities	$424,454	$617,265	$543,966	$1,073,367	$2,659,052
As of 31 March 2024					
Loans	$6,933,400	$2,488,142	$450,122	—	$9,871,664
Corporate bonds payable	$14,880	$2,414,880	—	—	$2,429,760
Amounts payables	$28,573,143	—	—	—	$28,573,143
Lease liabilities	$302,870	$490,118	$201,937	$288,422	$1,288,347

(6) Reconciliation of liabilities arising from financing activities

Reconciliation of liabilities for the three-month period ended 31 March 2025:

	Short-term borrowings	Corporate bonds payable	Long-term borrowings	Lease liabilities
As at 1 Jan 2025	$9,585,252	$2,400,000	$4,493,416	$2,296,152
Cash flows	476,201	—	77,484	(105,264)
Non-cash changes	163,894	—	3,774	205,272
As at 31 Mar 2025	$10,225,347	$2,400,000	$4,574,674	$2,396,160

	Guarantee Deposits	Total liabilities from financing activities
As at 1 Jan 2025	$38,659	$18,813,479
Cash flows	787	449,208
Non-cash changes	—	372,840
As at 31 Mar 2025	$39,446	$19,635,627

Reconciliation of liabilities for the three-month period ended 31 Mar 2024:

	Short-term borrowings	Short-term note payables	Corporate bonds payable	Long-term borrowings	Lease liabilities
As at 1 Jan 2024	$6,765,540	$30,000	$2,400,000	$3,764,150	$1,123,480
Cash flows	(956,188)	(30,000)	—	(121,673)	(67,649)
Non-cash changes	85,008	—	—	9,396	85,258
As at 31 Mar 2024	$5,894,360	—	$2,400,000	$3,651,873	$1,141,089

	Guarantee Deposits	Total liabilities from financing activities
As at 1 Jan 2024	$35,503	$14,118,673
Cash flows	711	(1,174,799)
Non-cash changes	—	179,662
As at 31 Mar 2024	$36,214	$13,123,536

(7) Fair values of financial instruments

A. The methods and assumptions applied in determining the fair value of financial instruments:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following methods and assumptions were used by the Group to measure or disclose the fair values of financial assets and financial liabilities:

(a) The carrying amount of cash and cash equivalents, accounts receivables, accounts payable and other current liabilities approximate their fair value due to their short maturities.

(b) Fair value of equity instruments without market quotations (including private placement of listed equity securities, unquoted public company and private company equity securities) are estimated using the market method valuation techniques based on parameters such as prices based on market transactions of equity instruments of identical or comparable entities and other relevant information (for example, inputs such as discount for lack of marketability, P/E ratio of similar entities and Price-Book ratio of similar entities).

B. Fair value of financial instruments measured at amortized cost

The carrying amount of financial assets and financial liabilities measured at amortized cost approximate their fair value due to their short maturities.

C. Fair value measurement hierarchy for financial instruments

Please refer to Note 12.8 for fair value measurement hierarchy for financial instruments of the Group.

(8) Fair value measurement hierarchy

A. Fair value measurement hierarchy

All asset and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole. Level 1, 2 and 3 inputs are described as follows:

Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities that the entity can access at the measurement date
Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
Level 3 – Unobservable inputs for the asset or liability

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Group determines whether transfers have occurred between Levels in the hierarchy by re-assessing categorization at the end of each reporting period.

B. Fair value measurement hierarchy of the Group's assets and liabilities

The Group does not have assets that are measured at fair value on a non-recurring basis. Fair value measurement hierarchy of the Group's assets and liabilities measured at fair value on a recurring basis is as follows:

As at 31 March 2025

	Level 1	Level 2	Level 3	Total
Financial assets:				
Financial assets at fair value through other comprehensive income				
Equity instrument measured at fair value through other comprehensive income	$308,223	–	$127,516	$435,739

As at 31 December 2024

	Level 1	Level 2	Level 3	Total
Financial assets:				
Financial assets at fair value through other comprehensive income				
Equity instrument measured at fair value through other comprehensive income	$368,257	–	$125,406	$493,663

As at 31 March 2024

Financial assets:				
Financial assets at fair value through profit or loss				
Financial assets at fair value through other comprehensive income				
Equity instrument measured at fair value through other comprehensive income	–	–	$161,236	$161,236

C. Reconciliation for fair value measurements in Level 3 is as follows:

	Financial assets at fair value through other comprehensive income
As at 1 Jan 2025	$125,406
Unrealized income from equity instruments investments measured at fair value through other comprehensive income	1,606
Other	504
As at 31 Mar 2025	$127,516

	Financial assets at fair value through other comprehensive income
As at 1 Jan 2024	$164,310
Unrealized income from equity instruments investments measured at fair value through other comprehensive income	(4,631)
Other	1,557
As at 31 Mar 2024	$161,236

D. Information on significant unobservable inputs of fair value measurement in Level 3 fair value hierarchy:

Significant unobservable inputs of fair value measurement in Level 3 fair value hierarchy are as follows :

As at 31 March 2025:

	Valuation techniques	Significant unobservable inputs	Quantitative information	Correlation between inputs and fair value	Sensitivity Analysis of correlation between inputs and fair value
Financial assets:					
Financial assets at fair value through other comprehensive income stocks	Market approach and net asset approach	Discount for lack of marketability	35%	The greater degree of lack of marketability, the lower the estimated fair value is determined.	1% strengthens (weakens) in the discount for lack of marketability would result in (decreased) increased in the Group's profit or loss by $575 thousand.

As at 31 December 2024:

	Valuation techniques	Significant unobservable inputs	Quantitative information	Correlation between inputs and fair value	Sensitivity Analysis of correlation between inputs and fair value
Financial assets:					
Financial assets at fair value through other comprehensive income stocks	Market approach and net asset approach	Discount for lack of marketability	35%	The greater degree of lack of marketability, the lower the estimated fair value is determined.	1% strengthens (weakens) in the discount for lack of marketability would result in (decreased) increased in the Group's profit or loss by $563 thousand.

As at 31 March 2024:

	Valuation techniques	Significant unobservable inputs	Quantitative information	Correlation between inputs and fair value	Sensitivity Analysis of correlation between inputs and fair value
Financial assets:					
Financial assets at fair value through other comprehensive income stocks	Market approach and net asset approach	Discount for lack of marketability	35%	The greater degree of lack of marketability, the lower the estimated fair value is determined.	1% strengthens (weakens) in the discount for lack of marketability would result in (decreased) increased in the Group's profit or loss by $857 thousand.

(9) Significant assets and liabilities denominated in foreign currencies

Information regarding the significant assets and liabilities denominated in foreign currencies is listed below:

	31 March 2025		
	Foreign currencies (in thousands)	Foreign exchange rate	NT$ (in thousands)
Financial assets			
Monetary items:			
USD	$709,803	33.2050	$23,569.013
RMB	$4,258,998	4.5730	$19,476.396
Financial liabilities			
Monetary items:			
USD	$502,461	33.2050	$16,684,231
RMB	$5,895,368	4.5730	$26,959,518

	31 December 2024		
	Foreign currencies (in thousands)	Foreign exchange rate	NT$ (in thousands)
Financial assets			
Monetary items:			
USD	$629,985	32.7850	$20,654,047
RMB	$3,829,593	4.4780	$17,148,919
Financial liabilities			
Monetary items:			
USD	$290,440	32.7850	$9,522,089
RMB	$5,130,990	4.4780	$22,976,575

	31March 2024		
	Foreign currencies (in thousands)	Foreign exchange rate	NT$ (in thousands)
Financial assets			
Monetary items:			
USD	$516,049	32.0000	$16,513,556
RMB	$4,057,372	4.4080	$17,884,897
Financial liabilities			
Monetary items:			
USD	$385,832	32.0000	$12,346,636
RMB	$3,568,411	4.4080	$15,729,557

The Group's functional currency are various, and hence is not able to disclose the information of exchange gains and losses by each significant assets and liabilities denominated in foreign currencies. The foreign exchange loss was 69,687 thousand and 120,981 thousand for the three-month periods ended 31 March 2025 and 2024, respectively.

(10) Capital management

The primary objective of the Group's capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and maximize shareholder value. The Group manages its capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust dividend payment to shareholders, returning capital to shareholders or issuing new shares.

13. Other disclosure

(1) Information at significant transactions and on investees

A. Financing provided to others for the three -month periods ended 31 March 2025: Please refer to Attachment 1.
B. Endorsement/Guarantee provided to others for the three-month periods ended 31 March 2025: Please refer to Attachment 2.
C. Securities held as of 31 March 2025: Please refer to Attachment 3.
D. Related party transactions for purchases and sales amounts exceeding the lower of NT$100 million or 20% of the capital stock for the three -month periods ended 31 March 2025: Please refer to Attachment 4.
E. Receivables from related parties with amounts exceeding the lower of NT$100 million or 20% of capital stock as of 31 March 2025: Please refer to Attachment 5.
F. Direct or indirect significant influence or control over the investees for the three-month periods ended 31 March 2025 (excluding investments in China): Please refer to Attachment 6.
G. Others: Significant inter-company transactions during the reporting periods: Please refer to Attachment 8.

(2) Information on investments in mainland China

A. Information on investments in mainland China: Please refer to Attachment 7.
B. Significant transactions with the investee companies in China directly or indirectly through the third area and the relevant prices, payment terms and unrealized gains and losses:
(a)Purchase, ending balance of related payables and their weightings: Please refer to Attachment 4.
(b)Sales, the ending balance of related receivables and their weightings: Please refer to Attachment 4.
(c)Ending balance of endorsements/guarantees or collateral provided and the purposes: Please refer to Attachment 2.
(d)Transactions that have significant impact on the profit or loss of current period or the financial position: None.

14. Segment information

For management purposes, the Group is organized into business units based on their products and services and has two reportable operating segments as follows:

(1) General management segment:
The general management segment is responsible for the Group's operation planning and owns manufacturing, R&D and sales functions.

(2) Overseas segment:
The overseas segment owns manufacturing and sales functions.

No operating segments have been aggregated to form the above reportable operating segments.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment.

Segment performance is evaluated based on operating profit or loss and is measured based on accounting policies consistent with those in the consolidated financial statements.

However, finance costs, financial benefits and income taxes are managed on a group basis and are not allocated to operating segments.

Transfer prices between operating segment are on an arm's length basis in a manner similar to transactions with third parties.

For the three-month period ended 31 March 2025

	Overseas	General management	Adjustment and elimination	Total
Revenue				
External customer	$5,557,130	$17,775.821	—	$23,332,951
Inter-segment (Note)	22,009,072	1,123,883	($23,132,955)	—
Total revenue	$27,566,202	$18,899,704	($23,132,955)	$23,332,951
Segment profit	$2,071,036	$2,593,617	($44,292)	$4,620,361

Note: Inter-segment revenues were eliminated on consolidation.

For the three-month period ended 31 March 2024

	Overseas	General management	Adjustment and elimination	Total
Revenue				
External customer	$4,481,067	$10,827,621	—	$15,308,688
Inter-segment (Note)	11,433,840	726,873	($12,160,713)	—
Total revenue	$15,914,907	$11,554,494	($12,160,713)	$15,308,688
Segment profit	$1,247,550	$1,056,336	$25,722	$2,329,608

Note: Inter-segment revenues were eliminated on consolidation.

As of 31 March 2025, 31 December 2024 and 31 March 2024, the assets of reportable segment information were as follows:

	Overseas	General management	Adjustment and elimination	Total
31 March 2025 Assets	$85,980,454	$54,066,529	($28,222,321)	$111,824,662
31 December 2024 Assets	$78,122,000	$46,102,974	($24,319,413)	$99,905,561
31 March 2024 Assets	$57,240,268	$34,084,938	($16,538,957)	$74,786,249

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

FINANCING PROVIDED TO OTHERS

TABLE 1

No (Note 1)	Financing Company	Counter-party	Financial Statement Account (Note 2)	Related Party	Maximum Balance for the Period (Note 3)	Ending Balance (Note 8)	Amount Actually Drawn	Interest Rate	Accumulated Outflow of Investment from Taiwan as of March 31, 2025 (Note 4)	Transaction Amounts (Note 5)	Reason for Financing (Note 6)	Allowance for Doubtful Accounts	Collateral		Financing Limits for Each Borrower	Financing Company's Total Financing Amount Limits	Note
													Item	Value			
1	MACE TECH CORP.	WUCHIDA INTERNATIONAL CO., LTD.	Other receivables	Yes	$116,218 (USD3,500 thousand)	$116,218 (USD3,500 thousand)	$116,218 (USD3,500 thousand)	0.00%	2	–	Operating capital	–	–	–	$1,991,028	$1,991,028	(Note 7)
2	CHIHUNG INTERNATIONAL LTD.	JADS CORPORATION (HK) LIMITED	Other receivables	Yes	$166,025 (USD5,000 thousand)	$166,025 (USD5,000 thousand)	$166,025 (USD5,000 thousand)	0.00%	2	–	Operating capital	–	–	–	$2,967,749	$2,967,749	(Note 7)

Note 1： Companies are coded as follows：

(1) ASIA VITAL COMPONENTS Co., LTD. is coded "0".

(2) The investees are coded from "1" in the order presented in the table above.

Note 2：Receivables from affiliates and related parties, shareholder transactions, prepayments and temporary payments etc. are required to be disclosed in this field if they are financings provided to others.

Note 3：The maximum balance of financing provided to others for the three-month ended March 31, 2025.

Note 4：Nature of Financing are coded as follows：

(1) Business transaction is coded "1".

(2) Short-term financing is coded "2".

Note 5：If nature of financing is business transaction, the amount of transaction should be disclosed.

Note 6：With respect to short-term financing, the reasons of financing and the purpose of use by the counter-party shall be specified, such as loan repayment, equipment acquisition or operating capital.

Note 7：ASIA VITAL COMPONENTS CO., LTD : The financing provided to any single entity shall not exceed 40% of the net worth. Total financing shall not exceed 40% of the net worth.

Note 8： D-MAX TECHNOLOGY CO., LTD. AND FOSITEK CORP. : The financing provided to any single entity shall not exceed 40% of the net worth. Total financing shall not exceed 40% of the net worth.

Note 9：If public companies, pursuant to Paragraph 1, Article 14 of Regulations Governing Loaning of Funds and Making of Endorsements / Guarantees by Public Companies, resolve each individual lending at the board meetings, the amounts resolved (before any drawing) shall be the publicly-announced balance to disclose the risk they assume; provided however, if any repayment is made subsequently, the outstanding balance after such repayment shall be disclosed to reflect the risk adjusted. If public companies, pursuant to Paragraph 2, Article 14 of the same Regulations, authorize the chairperson by board resolution, within a certain monetary limit and a period not to exceed one year, to give loans in instalments or to make a revolving credit line available, the amount resolved shall be the publicly-announced balance. Although repayment may be made subsequently, as drawings are likely to happen, the amount of financing resolved by the board shall be recorded as the publicly-announced balance.

Note 10：All the above transactions were eliminated on consolidation.

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

ENDORSEMENT/GUARANTEE PROVIDED TO OTHERS

TABLE 2

No (Note 1)	Endorsement/Guarantee Provider	Guaranteed Party		Limits on Endorsement/Guarantee Amount Provided to Each Guaranteed Party (Note 3&4)	Maximum Balance for the Period (Note 12)	Ending Balance (Note 13)	Amount Actually Drawn (Note 14)	Amount of Endorsement/ Guarantee secured by Properties	Accumulated Outflow of Investment from Taiwan as of March 31, 2024	Maximum Endorsement/ Guarantee Amount Allowed (Note 3&4)	Endorsement provided by parent company to subsidiaries (Note 15)	Endorsement provided by subsidiaries to parent company (Note 15)	Carrying Amount as of March 31, 2025 (Note 15)	Note
		Name	Nature of Relationship (Note 2)											
0	ASIA VITAL COMPONENTS CO.,LTD	AVC PRECISION, CO., LTD.	2	$28,847,252	$457,300 (CNY100,000 thousand)	$457,300 (CNY100,000 thousand)	$108,101 (CNY23,639 thousand)	—	1.59%	$43,270,879	Y	N	Y	(Note 3)
0	ASIA VITAL COMPONENTS CO.,LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	2	$28,847,252	$2,283,575 (USD55,000 thousand) (CNY100,000 thousand)	$2,283,575 (USD55,000 thousand) (CNY100,000 thousand)	$681,377 (CNY149,000 thousand)	—	7.92%	$43,270,879	Y	N	Y	(Note 3)
0	ASIA VITAL COMPONENTS CO.,LTD	AVC TECH. (VIETNAM) CO., LTD.	2	$28,847,252	$13,746,870 (USD414,000 thousand)	$13,746,870 (USD414,000 thousand)	$7,661,983 (USD183,777 thousand) (VND1,218,483,515 thousand)	—	47.65%	$43,270,879	Y	N	N	(Note 3)

Note 1：Companies are coded as follows:

(1) ASIA VITAL COMPONENTS Co., LTD. is coded "0".

(2) The investees are coded from "1" in the order presented in the table above.

Note 2：The relationships between endorsement/guarantee providers and guaranteed parties are categorized into the following types :

(1) A company that has a business relationship with AVC.

(2) A subsidiary in which AVC holds directly over 50% of common equity interest.

(3) An investee in which AVC and its subsidiaries jointly hold over 50% of common equity interest.

(4) A parent company that holds directly over 90% or indirectly over 90% through a subsidiary of the company's common equity interest.

(5) A company that has provided guarantees to AVC, and vice versa, due to contractual requirements.

(6) A company in which AVC jointly invests with other shareholders, and for which AVC has provided endorsement/guarantee in proportion to its shareholding percentage.

(7) Companies in the same industry provide among themselves joint and several security for a perfomance guarantee of a sales contract for pre-construction homes pursunat to the Consumer Protection Act for each other.

Note 3：ASIA VITAL COMPONENTS CO.,LTD.：The aggregate amount of endorsements/guarantees for any single entity shall not exceed 20% of the Company's net worth, and the aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth.

The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note 4：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (DONGGUAN) CO., LTD., AVC PRECISION, CO., LTD. :

The amount of guarantees/endorsements provided to any single entity shall not exceed USD200 million dollars.

FOSITEK CORP.：The aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth. The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note5：AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., is CNY120 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note6：ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (CHINA) CO., LTD., is CNY180 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note7：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to AVC PRECISION, CO., LTD. is CNY80 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note8：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY70 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note9：AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY40 million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note10：ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to AVC PRECISION, CO., LTD. is CNY27million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note11：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to AVC OPTICS (WUHAN) CORP. is CNY50 million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note12：Maximum balance of endorsements/guarantees provided to others for current period.

Note13：The maximum balance for the period and ending balance represent the amounts approved by the Board Directors.

Note14：The company which endorsements/guarantees by AVC should disclosed the amount actually drawn within ending balance.

Note15：Public company provided endorsements/guarantees to subsidiary or subsidiary provided endorsements/guarantees to public company or provided endorsements/guarantees which located in CHINA area coded "Y".

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

ENDORSEMENT/GUARANTEE PROVIDED TO OTHERS

TABLE 2-1

No (Note 1)	Endorsement/Guarantee Provider	Guaranteed Party		Limits on Endorsement/Guarantee Amount Provided to Each Guaranteed Party (Note 3&4)	Maximum Balance for the Period (Note 12)	Ending Balance (Note 13)	Amount Actually Drawn (Note 14)	Amount of Endorsement/ Guarantee secured by Properties	Accumulated Outflow of Investment from Taiwan as of March 31, 2024	Maximum Endorsement/ Guarantee Amount Allowed (Note 3&4)	Endorsement provided by parent company to subsidiaries (Note 15)	Endorsement provided by subsidiaries to parent company (Note 15)	Carrying Amount as of March 31, 2025 (Note 15)	Note
		Name	Nature of Relationship (Note 2)											
1	AVC OPTICS (WUHAN) CORP.	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	4	$6,641,000 (USD200,000 thousand)	$548,760 (CNY120,000 thousand)	$548,760 (CNY120,000 thousand)	$548,275 (CNY119,894 thousand)	–	16.51%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、5)
2	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	4	$6,641,000 (USD200,000 thousand)	$548,760 (CNY120,000 thousand)	$548,760 (CNY120,000 thousand)	$548,275 (CNY119,894 thousand)	–	25.99%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、5)
2	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	4	$6,641,000 (USD200,000 thousand)	$823,140 (CNY180,000 thousand)	$823,140 (CNY180,000 thousand)	$700,110 (CNY153,096 thousand)	–	38.99%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、6)
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC OPTICS (WUHAN) CORP.	4	$6,641,000 (USD200,000 thousand)	$914,600 (CNY200,000 thousand)	$914,600 (CNY200,000 thousand)	$191,648 (CNY41,909 thousand)	–	13.77%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、 11)
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC PRECISION, CO., LTD.	4	$6,641,000 (USD200,000 thousand)	$365,840 (CNY80,000 thousand)	$365,840 (CNY80,000 thousand)	$133,779 (CNY29,254 thousand)	–	5.51%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、7)
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	4	$6,641,000 (USD200,000 thousand)	$320,110 (CNY70,000 thousand)	$320,110 (CNY70,000 thousand)	$276,567 (CNY60,478 thousand)	–	4.82%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、8)
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	4	$6,641,000 (USD200,000 thousand)	$1,966,389 (CNY430,000 thousand)	$1,966,389 (CNY430,000 thousand)	$1,109,897 (CNY242,707 thousand)	–	29.61%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、6)
4	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	$6,641,000 (USD200,000 thousand)	$1,370,391 (CNY299,670 thousand)	$1,370,391 (CNY299,670 thousand)	$783,000 (CNY171,222 thousand)	–	93.81%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、8、9)

Note 1：Companies are coded as follows:

(1) ASIA VITAL COMPONENTS Co., LTD. is coded "0".

(2) The investees are coded from "1" in the order presented in the table above.

Note 2：The relationships between endorsement/guarantee providers and guaranteed parties are categorized into the following types :

(1) A company that has a business relationship with AVC.

(2) A subsidiary in which AVC holds directly over 50% of common equity interest.

(3) An investee in which AVC and its subsidiaries jointly hold over 50% of common equity interest.

(4) A parent company that holds directly over 90% or indirectly over 90% through a subsidiary of the company's common equity interest.

(5) A company that has provided guarantees to AVC, and vice versa, due to contractual requirements.

(6) A company in which AVC jointly invests with other shareholders, and for which AVC has provided endorsement/guarantee in proportion to its shareholding percentage.

(7) Companies in the same industry provide among themselves joint and several security for a perfomance guarantee of a sales contract for pre-construction homes pursunat to the Consumer Protection Act for each other.

Note 3：ASIA VITAL COMPONENTS CO.,LTD.：The aggregate amount of endorsements/guarantees for any single entity shall not exceed 20% of the Company's net worth, and the aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth.

The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note 4：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (DONGGUAN) CO., LTD., AVC PRECISION, CO., LTD. :

The amount of guarantees/endorsements provided to any single entity shall not exceed USD200 million dollars.

FOSITEK CORP. ：The aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth. The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note5：AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., is CNY120 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note6：ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (CHINA) CO., LTD., is CNY180 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note7：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to AVC PRECISION, CO., LTD. is CNY80 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note8：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY70 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note9：AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY40 million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note10：ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to AVC PRECISION, CO., LTD. is CNY27million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note11：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to AVC OPTICS (WUHAN) CORP. is CNY50 million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note12：Maximum balance of endorsements/guarantees provided to others for current period.

Note13：The maximum balance for the period and ending balance represent the amounts approved by the Board Directors.

Note14：The company which endorsements/guarantees by AVC should disclosed the amount actually drawn within ending balance.

Note15：Public company provided endorsements/guarantees to subsidiary or subsidiary provided endorsements/guarantees to public company or provided endorsements/guarantees which located in CHINA area coded "Y".

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

ENDORSEMENT/GUARANTEE PROVIDED TO OTHERS

TABLE 2-2

No (Note 1)	Endorsement/Guarantee Provider	Guaranteed Party		Limits on Endorsement/Guarantee Amount Provided to Each Guaranteed Party (Note 3&4)	Maximum Balance for the Period (Note 12)	Ending Balance (Note 13)	Amount Actually Drawn (Note 14)	Amount of Endorsement/ Guarantee secured by Properties	Accumulated Outflow of Investment from Taiwan as of March 31, 2025	Maximum Endorsement/ Guarantee Amount Allowed (Note 3&4)	Endorsement provided by parent company to subsidiaries (Note 15)	Endorsement provided by subsidiaries to parent company (Note 15)	Carrying Amount as of March 31, 2025 (Note 15)	Note
		Name	Nature of Relationship (Note 2)											
5	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC PRECISION, CO., LTD.	2	$6,641,000 (USD200,000 thousand)	$1,102,093 (CNY241,000 thousand)	$999,200 (CNY218,500 thousand)	$621,469 (CNY135,900 thousand)	–	21.74%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、7、10)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	AVC OPTICS (WUHAN) CORP.	4	$6,641,000 (USD200,000 thousand)	$228,650 (CNY50,000 thousand)	$228,650 (CNY50,000 thousand)	$26,981 (CNY5900 thousand)	–	3.21%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、11)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	4	$6,641,000 (USD200,000 thousand)	$457,300 (CNY100,000 thousand)	$457,300 (CNY100,000 thousand)	$252,118 (CNY55,132 thousand)	–	6.43%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	4	$6,641,000 (USD200,000 thousand)	$1,463,360 (CNY320,000 thousand)	$1,463,360 (CNY320,000 thousand)	$1,462,082 (CNY319,721 thousand)	–	20.57%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、5)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	AVC PRECISION, CO., LTD.	4	$6,641,000 (USD200,000 thousand)	$489,311 (CNY107,000 thousand)	$489,311 (CNY107,000 thousand)	$133,779 (CNY29,254 thousand)	–	6.88%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、7、10)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	4	$6,641,000 (USD200,000 thousand)	$503,030 (CNY110,000 thousand)	$503,030 (CNY110,000 thousand)	$276,567 (CNY60,478 thousand)	–	7.07%	$6,641,000 (USD200,000 thousand)	N	N	Y	(Note 4、8、9)
7	FOSITEK CORP.	SHENZHEN FOSITEK TELECOME CO.,LTD.	2	$5,435,181	$442,590 (USD3,000 thousand) (CNY75,000 thousand)	$342,975 – (CNY75,000 thousand)	–	–	6.31%	$8,152,771	N	N	Y	(Note 4)
7	FOSITEK CORP.	FOSITEK (VIET NAM) COMPANY LIMITED	2	$5,435,181	$929,740 (USD28,000 thousand)	$929,740 (USD28,000 thousand)	$21,877 (USD659 thousand)	–	17.11%	$8,152,771	N	N	Y	(Note 4)

Note 1：Companies are coded as follows:

(1) ASIA VITAL COMPONENTS Co., LTD. is coded "0".

(2) The investees are coded from "1" in the order presented in the table above.

Note 2：The relationships between endorsement/guarantee providers and guaranteed parties are categorized into the following types :

(1) A company that has a business relationship with AVC.

(2) A subsidiary in which AVC holds directly over 50% of common equity interest.

(3) An investee in which AVC and its subsidiaries jointly hold over 50% of common equity interest.

(4) A parent company that holds directly over 90% or indirectly over 90% through a subsidiary of the company's common equity interest.

(5) A company that has provided guarantees to AVC, and vice versa, due to contractual requirements.

(6) A company in which AVC jointly invests with other shareholders, and for which AVC has provided endorsement/guarantee in proportion to its shareholding percentage.

(7) Companies in the same industry provide among themselves joint and several security for a perfomance guarantee of a sales contract for pre-construction homes pursunat to the Consumer Protection Act for each other.

Note 3：ASIA VITAL COMPONENTS CO.,LTD.：The aggregate amount of endorsements/guarantees for any single entity shall not exceed 20% of the Company's net worth, and the aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth.

The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note 4：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (DONGGUAN) CO., LTD., AVC PRECISION, CO., LTD. :

The amount of guarantees/endorsements provided to any single entity shall not exceed USD200 million dollars.

FOSITEK CORP.：The aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth. The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note5：AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., is CNY120 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note6：ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (CHINA) CO., LTD., is CNY180 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note7：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to AVC PRECISION, CO., LTD. is CNY80 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note8：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY70 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note9：AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY40 million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note10：ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to AVC PRECISION, CO., LTD. is CNY27million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note11：ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guarnateed to AVC OPTICS (WUHAN) CORP. is CNY50 million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note12：Maximum balance of endorsements/guarantees provided to others for current period.

Note13：The maximum balance for the period and ending balance represent the amounts approved by the Board Directors.

Note14：The company which endorsements/guarantees by AVC should disclosed the amount actually drawn within ending balance.

Note15：Public company provided endorsements/guarantees to subsidiary or subsidiary provided endorsements/guarantees to public company or provided endorsements/guarantees which located in CHINA area coded "Y".

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

MARKETABLE SECURITIES HELD (EXCLUDING INVESTMENTS IN SUBSIDIARIES, ASSOCIATES AND JOINTLY CONTROLLED ENTITIES)

TABLE 3

Name of Held Company	Type and name of Marketable Securities	Relationship with the Company	Financial Statement Account	March 31, 2025			
				Shares (In Thousands)	Carrying Amount	Percentage of Ownership	Market Value
ASIA VITAL COMPONENTS CO.,LTD	Listed (OTC) stocks						
	UBIQCONN TECHNOLOGY, INC.	–	Financial assets measured at fair value through other comprehensive income, noncurrent	4,140	$236,823	4.81%	$236,823
	Not listed (OTC) stocks						
	RTR-TECH TECHNOLOGY CO., LTD.	–	Financial assets measured at fair value through other comprehensive income, noncurrent	14,000	–	19.42%	–
	APTOS TECHNOLOGY INC.	–	Financial assets measured at fair value through other comprehensive income, noncurrent	450	–	0.74%	–
	WK TECHNOLOGY FUND IX II LTD.	–	Financial assets measured at fair value through other comprehensive income, noncurrent	3,000	$29,679	2.67%	$29,679
MERIT TRADING CORPORATION	Not listed (OTC) stocks						
	FURUKAWA ELECTRIC (SHENZHEN) CO., LTD.	Other related parties	Financial assets measured at fair value through other comprehensive income, noncurrent	(Note)	$87,546	9.06%	$87,546
MACE TECH CORP.	Not listed (OTC) stocks						
	SHENG-SHING WORLDWIDE CORP.	–	Financial assets measured at fair value through other comprehensive income, noncurrent	703	$10,291	14.06%	$10,291
ASIA VITAL COMPONENTS (CHINA) CO., LTD.	Not listed (OTC) stocks						
	SHENZHEN TIMELINK TECHNOLOGY CO., LTD.	–	Financial assets measured at fair value through other comprehensive income, noncurrent	2,273	–	10.80%	–
FOSITEK CORP.	Listed (TWSE) stocks						
	O-BANK	–	Financial assets measured at fair value through other comprehensive income, noncurrent	6,000	$71,400	0.18%	$71,400

Note：None amount of shares is issued publicly by Limited Company.

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

RELATED PARTY TRANSACTIONS WITH PURCHASE OR SALES AMOUNT OF AT LEAST NT$100 MILLION OR 20% OF THE PAID-IN CAPITAL

TABLE 4

Company Name	Related Party	Nature of Relationships	Transaction Details				Abnormal Transaction		Accumulated Outflow of Investment from Taiwan as of March 31, 2025		Note
			Purchases/ Sales	Amount	Percentage to Total	Collection/ Payment Terms	Unit Price	Collection/ Payment Terms	Ending Balance	Percentage to Total	
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	Subsidiary	(Purchases)	($352,083)	(2%)	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	($503,437)	(2%)	
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	Subsidiary	(Purchases)	($5,535,608)	(28%)	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	($8,883,033)	(39%)	
ASIA VITAL COMPONENTS CO., LTD	AVC OPTICS (WUHAN) CORP.	Subsidiary	(Purchases)	($687,069)	(3%)	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	($695,844)	(3%)	
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	Subsidiary	(Purchases)	($164,887)	(1%)	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	($235,098)	(1%)	
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	Subsidiary	(Purchases)	($7,043,125)	(35%)	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	($7,111,176)	(32%)	
ASIA VITAL COMPONENTS CO., LTD	(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	Subsidiary	(Purchases)	($314,338)	(2%)	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	($436,857)	(2%)	
ASIA VITAL COMPONENTS CO., LTD	AVC TECH. (VIETNAM) CO., LTD.	Subsidiary	(Purchases)	($5,346,644)	(27%)	Net 30 days from the end of the month of when invoice is issued by T/T	N/A	N/A	($3,592,136)	(16%)	
ASIA VITAL COMPONENTS CO., LTD	AVC AMERICA, INC.	Subsidiary	Sales	$828,540	5%	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	$672,921	30%	

(Continued)

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

RELATED PARTY TRANSACTIONS WITH PURCHASE OR SALES AMOUNT OF AT LEAST NT$100 MILLION OR 20% OF THE PAID-IN CAPITAL

TABLE 4-1

Company Name	Related Party	Nature of Relationships	Transaction Details				Abnormal Transaction		Accumulated Outflow of Investment from Taiwan as of March 31, 2025		Note
			Purchases/ Sales	Amount	Percentage to Total	Collection/ Payment Terms	Unit Price	Collection/ Payment Terms	Ending Balance	Percentage to Total	
ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	$352,083	87%	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	$503,437	84%	
ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	$5,535,608	96%	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	$8,883,033	96%	
AVC OPTICS (WUHAN) CORP.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	$687,069	73%	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	$695,844	77%	
ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	$164,887	5%	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	$235,098	7%	
ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	$7,043,125	99%	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	$7,111,176	95%	
(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	$314,338	81%	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	$436,857	85%	
AVC TECH. (VIETNAM) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	$5,226,871	100%	Net 30 days from the end of the month of when invoice is issued by T/T	N/A	N/A	$3,592,136	94%	
AVC AMERICA, INC.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	(Purchases)	($828,540)	(99%)	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	($672,921)	(99%)	

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

RECEIVABLES FROM RELATED PARTIES OF AT LEAST NT$100 MILLION OR 20% OF THE PAID-IN CAPITAL

TABLE 6

Company Name	Related Party	Nature of Relationships	Ending Balance (Note 3)	Turnover Ratio (times)	Overdue		Amounts Received in Subsequent Periods	Allowance for Doubtful Accounts
					Amount	Action Taken		
ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	$503,437	0.68	—	(Note 2)	$143,425	(Note 1)
ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	$8,883,033	0.68	—	(Note 2)	$1,640,187	(Note 1)
AVC OPTICS (WUHAN) CORP.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	$695,844	1.02	—	(Note 2)	$237,167	(Note 1)
ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	$235,098	0.70	—	(Note 2)	$66,566	(Note 1)
ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	$7,111,176	1.11	—	(Note 2)	$2,057,220	(Note 1)
(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	$436,857	0.65	—	(Note 2)	$151,977	(Note 1)
AVC TECH. (VIETNAM) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	$3,592,136	1.62	—	(Note 2)	$1,515,865	(Note 1)
ASIA VITAL COMPONENTS CO., LTD	AVC AMERICA, INC.	Subsidiary	($672,921)	1.25	—	(Note 2)	—	(Note 1)

Note 1：The preparation of consolidated statements does not require recording the allowance for doubtful accounts.

Note 2：The Company balances its accounts regularly and writes off receivables against payables.

Note 3：All the above transactions were eliminated on consolidation.

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

NAMES, LOCATIONS AND RELATED INFORMATION OF INVESTEE COMPANIES (Not including investment in Mainland China)

TABLE 6

Investor Company	Investee Company	Address	Main businesses and products	Initial Investment		Investment as of March 31, 2025			Accumulated Outflow of Investment from Taiwan as of March 31, 2025	Investment income (loss) recognized	Note
				Ending balance	Beginning balance	Number of shares (thousand)	Percentage of ownership (%)	Carrying amount			
ASIA VITAL COMPONENTS CO., LTD	AVC INTERNATIONAL CO., LTD.－B.V.I.	British Virgin Islands	Investment holding	$5,147,294	$5,147,294	16	100.00%	$15,217,709	$811,626	$660,703	
	CHIHUNG INTERNATIONAL LTD.	Samoa	Investment holding	$1,040,647	$1,040,647	32,770	100.00%	$7,396,520	$59,027	$60,435	
	MERIT TRADING CORPORATION	Samoa	Trade	$29,088	$29,088	892	100.00%	$84,378	($1)	($1)	
	RAYNEY INTERNATIONAL LTD.	Samoa	Trade	$78,950	$78,950	2,400	100.00%	$343,297	$41,256	$41,256	
	AVC AMERICA, INC.	USA	Trade	$91,903	$91,903	41	100.00%	$210,310	$12,538	$12,538	
	AVC INTERNATIONAL (SAMOA) CO., LTD.	Samoa	Trade	$10,157	$10,157	300	100.00%	$12,875	$1	$99	
	JADS CORPORATION (HK) LTD.	Hongkong	Trade	$327	$327	10	100.00%	$31,739	$56	$56	
	ZIMAG TECHNOLOGY CO., INC.	Taoyuan City, Taiwan	Manufacture, process and sales of molds and aluminum products	$45,000	$45,000	2,700	9.53%	$53,193	$7,853	$848	
	AVC INTERNATIONAL CO., LTD.－SAMOA	Samoa	Trade	$32,120	$32,120	1,000	100.00%	$38,225	$2	$2	
	FOSITEK CORP.	New Taipei City, Taiwan	Sales and manufacture of electronic parts, computers and related products	$209,829	$209,829	11,567	16.87%	$930,350	$356,501	$60,409	
	HUNG YE INVESTMENT CO., LTD.	New Taipei City, Taiwan	Investment holding	$60,000	$60,000	6,000	100.00%	$5,409	($12)	($12)	
	D-MAX TECHNOLOGY CO., LTD.	New Taipei City, Taiwan	Sales and manufacture of electronic parts and related products	$201,035	$201,035	28,500	100.00%	$446,628	$21,875	$25,725	
	AVC EUROPE TECHNOLOGY GMBH	Germany	Trade	$9,050	$9,050	250	100.00%	$9,402	$7	$7	
	AVC TECH. (VIETNAM) CO., LTD.	Vietnam	Sales and manufacture of electronic	$3,028,417	$3,028,417	(Note)	100.00%	$2,892,594	$309,580	$357,623	
	PARAGON SEMICONDUCTOR LIGHTING TECHNOLOGY CO., LTD.	New Taipei City, Taiwan	Manufacture of industrial lighting equipment	$50,000	$50,000	5,000	40.00%	$39,887	$961	$385	

Note：None amount of shares is issued publicly by Limited Company.

(Continued)

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

NAMES, LOCATIONS AND RELATED INFORMATION OF INVESTEE COMPANIES (Not including investment in Mainland China)

TABLE 6-1

Investor Company	Investee Company	Address	Main businesses and products	Initial Investment		Investment as of March 31, 2025			Accumulated Outflow of Investment from Taiwan as of March 31, 2025	Investment income (loss) recognized	Note
				Ending balance	Beginning balance	Number of shares (thousand)	Percentage of ownership (%)	Carrying amount			
AVC INTERNATIONAL CO., LTD.－B.V.I.	MACE TECH CORP.	British Virgin Islands	Trade	$319,776	$319,776	11,068	100.00%	$4,977,572	$278,890	$278,890	
	AVC OPTICS CORP.	Cayman Islands	Investment holding	$3,128,775	$3,128,775	100,000	100.00%	$3,324,790	$41,951	$41,951	
HUNG YE INVESTMENT CO., LTD.	KEY APPLICATION TECHNOLOGY CO., LTD.	Hsinchu City, Taiwan	Sales and manufacture of electronic products	$15,300	$15,300	1,115	16.31%	—	($3,898)	—	
D-MAX TECHNOLOGY CO., LTD.	WUCHIDA INTERNATIONAL CO., LTD.	Samoa	Investment holding	$132,004	$132,004	4,000	100.00%	$497,129	$26,953	$26,953	
WUCHIDA INTERNATIONAL CO., LTD.	D-MAX INTERNATIONAL CO., LIMITED	Hongkong	Investment holding	$132,004	$132,004	4,000	100.00%	$439,472	$26,944	$26,944	
FOSITEK CORP.	MARKETHILL INVESTMENTS LTD.	Samoa	Investment holding	$949,097	$949,097	33,200	100.00%	$4,581,686	$224,711	$231,949	
FOSITEK CORP.	FOSITEK (VIET NAM) COMPANY LIMITED	Vietnam	Sales and manufacture of rails and shafts	$59,430	$59,430	(Note)	100.00%	$223,609	$96,808	$65,723	
FOSITEK CORP.	FOSITEK AMERICA, INC.	USA	Sales of rails and shafts	$14,078	$14,078	(Note)	100.00%	$15,425	($888)	($888)	

Note：None amount of shares is issued publicly by Limited Company.

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

INFORMATION ON INVESTMENT IN MAINLAND CHINA

TABLE 7

Investor Company	Investee Company	Main Businesses and Products	Total Amount of Paid-in Capital	Method of Investment (Note 1)	Accumulated Outflow of Investment from Taiwan as of January 1, 2025	Investment Flows		Accumulated Outflow of Investment from Taiwan as of March 31, 2025	Percentage of Ownership (Direct or Indirect Investment)	Profits/ Losses of the Investee Company	Share of Profits/Losses	Carrying Amount as of March 31, 2025	Accumulated Inward Remittance of Earnings as of March 31, 2025
						Outflow	Inflow						
ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	Sales and manufacture of computers related products and computer cooling fans	$642,719	(2) AVC INTERNATIONAL CO., LTD.－B.V.I.	$642,719	－	－	$642,719	100.00%	$475,080	$475,080	$6,639,927	－
ASIA VITAL COMPONENTS CO. , LTD	FURUKAWA AVC ELECTRONICS (SUZHOU) CO., LTD.	Sales and manufacture of reflow machines, solder paste printers and notebook thermal modules	$267,247	(2) RAYNEY INTERNATIONAL LTD.	$54,176	－	－	$54,176	30.00%	$137,521	$41,256	$249,435	－
ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	Sales and manufacture of computers, electronic products and related parts	$514,105	(2) AVC INTERNATIONAL CO., LTD.－B.V.I.	$319,776	－	－	$319,776	100.00%	$279,199	$279,199	$4,654,404	－
ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	Sales and manufacture of computers related products and computer cooling fans	$879,291	(2) CHIHUNG INTERNATIONAL LTD.	$879,291	－	－	$879,291	100.00%	$58,978	$58,978	$7,115,159	－
ASIA VITAL COMPONENTS CO. , LTD	FURUKAWA ELECTRIC (SHENZHEN) CO., LTD.	Sales and manufacture of automobile parts	$321,060	(2) MERIT TRADING CORPORATION	$29,088	－	－	$29,088	9.06%	($73,817)	－	$87,546	－
ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	Sales and manufacture of computers, related parts and accessories	$1,055,897	(2) AVC INTERNATIONAL CO., LTD.－B.V.I.	$1,055,897	－	－	$1,055,897	100.00%	$15,651	$15,651	$2,111,306	－
D-MAX TECHNOLOGY CO., LTD.	(JIASHAN)D-MAX ELECTRONICS CO.,LTD.	Sales and manufacture of electronic and photographic equipment	$132,004	(2) WUCHIDA INTERNATIONAL CO., LTD.	$132,004	－	－	$132,004	100.00%	$26,944	$26,944	$439,054	－
ASIA VITAL COMPONENTS CO. , LTD	AVC OPTICS (WUHAN) CORP.	Sales and manufacture of computers related products and computer cooling fans	$3,128,775	(2) AVC INTERNATIONAL CO., LTD.－B.V.I.	$3,128,775	－	－	$3,128,775	100.00%	$41,951	$41,951	$3,324,777	－
FOSITEK CORP.	SHENZHEN FOSITEK TELECOME CO.,LTD.	Sales and manufacture of rails, shafts and metal stamping tooling	$846,331	(2) MARKETHILL INVESTMENTS LTD.	$846,331	－	－	$846,331	100.00%	$224,639	$224,639	$4,658,034	－

Accumulated Outflow of Investment from Taiwan to Mainland China as of MARCH 31, 2024	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment
$7,088,057 (USD 230,093,010)	$8,658,231 (USD 260,750,828)	(Note 3)

Note 1：The methods for investment in Mainland China are categorized into the following three types. Please specify the type.

(1) Direct investment in Mainland China.

(2) Indirectly investment in Mainland China through companies registered in the third area (Please specify the name of the company in third region).

(3) Others.

Note 2：The table is expressed in thousands of New Taiwan Dollars.

Note 3：The Company has obtained the certificate of being qualified for operating headquarters, issued by the Industrial Development Bureau, MOEA, the ceiling amount of the investment in Mainland China is not applicable to the Company.

Note 4：All the above transactions were eliminated on consolidation.

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS

TABLE 8

No. (Note 1)	Company Name	Counter Party	Nature of Relationship (Note 2)	Intercompany Transactions			
				Financial Statements Item	Amount	Terms	Percentage of Consolidated Net Revenue or Total Assets (Note 3)
0	ASIA VITAL COMPONENTS CO. , LTD	AVC AMERICA, INC.	1	Sales	$828,540	General trading terms	4%
0	ASIA VITAL COMPONENTS CO. , LTD	AVC AMERICA, INC.	1	Accounts receivable	$672,921	General trading terms	1%
0	ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	1	Purchases	$164,887	General trading terms	1%
0	ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	1	Accounts payable	$235,098	General trading terms	0%
0	ASIA VITAL COMPONENTS CO. , LTD	AVC OPTICS (WUHAN) CORP.	1	Purchases	$687,069	General trading terms	3%
0	ASIA VITAL COMPONENTS CO. , LTD	AVC OPTICS (WUHAN) CORP.	1	Accounts payable	$695,844	General trading terms	2%
0	ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	1	Purchases	$352,083	General trading terms	2%
0	ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	1	Accounts payable	$503,437	General trading terms	0%
0	ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	1	Purchases	$5,535,608	General trading terms	24%
0	ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	1	Accounts payable	$8,883,033	General trading terms	8%
0	ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	1	Purchases	$7,043,125	General trading terms	30%
0	ASIA VITAL COMPONENTS CO. , LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	1	Accounts payable	$7,111,176	General trading terms	6%
0	ASIA VITAL COMPONENTS CO. , LTD	AVC TECH. (VIETNAM) CO., LTD.	1	Purchases	$5,346,644	General trading terms	23%
0	ASIA VITAL COMPONENTS CO. , LTD	AVC TECH. (VIETNAM) CO., LTD.	1	Accounts payable	$3,592,136	General trading terms	3%
0	ASIA VITAL COMPONENTS CO. , LTD	(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	1	Purchases	$314,338	General trading terms	1%
0	ASIA VITAL COMPONENTS CO. , LTD	(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	1	Accounts payable	$436,857	General trading terms	0%

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS

TABLE 8-1

No. (Note 1)	Company Name	Counter Party	Nature of Relationship (Note 2)	Intercompany Transactions			
				Financial Statements Item	Amount	Terms	Percentage of Consolidated Net Revenue or Total Assets (Note 3)
1	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	Sales	$1,262,791	General trading terms	5%
1	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	Accounts receivable	$931,219	General trading terms	1%
1	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	3	Sales	$100,358	General trading terms	0%
1	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	3	Accounts receivable	$81,975	General trading terms	0%
1	AVC PRECISION, CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Sales	$262,950	General trading terms	1%
1	AVC PRECISION, CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts receivable	$604,054	General trading terms	1%
2	AVC OPTICS (WUHAN) CORP.	JADS CORPORATION (HK) LTD.	3	Purchases	$31,256	General trading terms	0%
2	AVC OPTICS (WUHAN) CORP.	JADS CORPORATION (HK) LTD.	3	Accounts payable	$16,618	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	3	Purchases	$4,927	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	3	Accounts payable	$149,297	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	JADS CORPORATION (HK) LTD.	3	Sales	$197,648	General trading terms	1%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	JADS CORPORATION (HK) LTD.	3	Accounts receivable	$197,823	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Purchases	$35,402	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts payable	$218,662	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Sales	$66,015	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts receivable	$149,977	General trading terms	0%
4	CHIHUNG INTERNATIONAL LTD.	JADS CORPORATION (HK) LTD.	3	Other receivable	$166,025	General trading terms	0%
5	JADS CORPORATION (HK) LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	Sales	$196,374	General trading terms	1%
5	JADS CORPORATION (HK) LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	Accounts receivable	$254,169	General trading terms	0%
6	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Sales	$229,733	General trading terms	1%
6	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts receivable	$315,209	General trading terms	0%
6	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Purchases	$43,929	General trading terms	0%
6	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts payable	$55,941	General trading terms	0%

Note 1： The parent company and its subsidiaries are coded as follows:
No.1. The parent company is coded "0".
No.2. The subsidiaries are coded consecutively beginning from "1" in the order presented in the table above.

Note 2： Transactions are categorized as follows:
No.1. Transactions from parent company to a subsidiary.
No.2. Transactions from subsidiary to the parent company.
No.3. Transactions between subsidiaries.

Note 3： Regarding the percentage of transaction amount to consolidated net revenue or total assets, it is computed based on the ending balance to consolidated total assets for balance sheet items; and based on interim accumulated amount to consolidated net revenue for income statement items.